Original Article
Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations
N Engl J Med 2002; 346:1616-1622May 23, 2002
- Abstract
Background
Data concerning the efficacy of bilateral prophylactic oophorectomy for reducing the risk of gynecologic cancer in women with BRCA1 or BRCA2 mutations are limited. We investigated whether this procedure reduces the risk of cancers of the coelomic epithelium and breast in women who carry such mutations.
Methods
A total of 551 women with disease-associated germ-line BRCA1 or BRCA2 mutations were identified from registries and studied for the occurrence of ovarian and breast cancer. We determined the incidence of ovarian cancer in 259 women who had undergone bilateral prophylactic oophorectomy and in 292 matched controls who had not undergone the procedure. In a subgroup of 241 women with no history of breast cancer or prophylactic mastectomy, the incidence of breast cancer was determined in 99 women who had undergone bilateral prophylactic oophorectomy and in 142 matched controls. The length of postoperative follow-up for both groups was at least eight years.
Results
Six women who underwent prophylactic oophorectomy (2.3 percent) received a diagnosis of stage I ovarian cancer at the time of the procedure; two women (0.8 percent) received a diagnosis of papillary serous peritoneal carcinoma 3.8 and 8.6 years after bilateral prophylactic oophorectomy. Among the controls, 58 women (19.9 percent) received a diagnosis of ovarian cancer, after a mean follow-up of 8.8 years. With the exclusion of the six women whose cancer was diagnosed at surgery, prophylactic oophorectomy significantly reduced the risk of coelomic epithelial cancer (hazard ratio, 0.04; 95 percent confidence interval, 0.01 to 0.16). Of 99 women who underwent bilateral prophylactic oophorectomy and who were studied to determine the risk of breast cancer, breast cancer developed in 21 (21.2 percent), as compared with 60 (42.3 percent) in the control group (hazard ratio, 0.47; 95 percent confidence interval, 0.29 to 0.77).
Conclusions
Bilateral prophylactic oophorectomy reduces the risk of coelomic epithelial cancer and breast cancer in women with BRCA1 or BRCA2 mutations.
Media in This Article
Table 1
Characteristics of the Group Studied to Determine the Risk of Ovarian Cancer.Table 2
Effect of Prophylactic Oophorectomy on the Risk of Ovarian and Breast Cancer, According to Selected Variables.Article Activity
- Article
Women with germ-line BRCA1 or BRCA2 mutations have an increased risk of breast and ovarian cancer as compared with the general population.1-3 These women often undergo bilateral prophylactic oophorectomy to reduce the risk of ovarian cancer. Nevertheless, the data on the resulting reduction in the risk of cancer are limited.4 Moreover, papillary serous peritoneal cancers, which arise from the same cell lineage as ovarian cancer and are clinically indistinguishable from stage III ovarian cancer,5-7 have been reported in women at high risk who have undergone the procedure.8,9 Prophylactic oophorectomy reduces the risk of breast cancer by about 50 percent in both carriers of BRCA1 mutations and genetically uncharacterized women.10-14 We determined the incidence of papillary serous peritoneal cancer after prophylactic oophorectomy in women with BRCA1 or BRCA2 mutations, as compared with the incidence of any cancer of the coelomic epithelium in women who did not undergo prophylactic oophorectomy. We also investigated whether prophylactic oophorectomy reduces the risk of breast cancer in women with BRCA1 or BRCA2 mutations, as we had previously observed in a subgroup of the current study population.10
Methods
Study Participants
Women with germ-line, disease-associated BRCA1 or BRCA2 mutations who reported having undergone prophylactic oophorectomy were identified from 11 North American and European registries (those of Creighton University, Dana–Farber Cancer Institute, Fox Chase Cancer Center, Georgetown University, the University of Chicago, the University of Pennsylvania, the University of Utah, Netherlands Cancer Institute, St. Mary's Hospital, Women's College Hospital, and Yale University). The BRCA1 or BRCA2 mutation status of all subjects was confirmed by direct mutation testing, with informed consent, under protocols approved by the human-subjects review boards at each institution. Women with BRCA1 or BRCA2 variants of unknown functional importance were excluded. Two samples of women who had undergone prophylactic oophorectomy and matched controls were used to evaluate the effect of prophylactic oophorectomy on the risk of ovarian and breast cancer. Potentially eligible controls were selected to be in the study sample at random and without replacement. One or more controls were selected for inclusion in the study sample if they could be matched to a subject who had undergone prophylactic oophorectomy according to type of mutation (BRCA1 or BRCA2), treatment center, and year of birth (within five years).
Study of Ovarian-Cancer Risk
Women were excluded from the study if they had undergone unilateral oophorectomy or had a history of ovarian cancer (including borderline tumors or tumors of low malignant potential) before undergoing prophylactic oophorectomy. Women were included in the group of subjects studied to determine the risk of ovarian cancer only if their surgery was not performed to treat ovarian cancer. A control was eligible if she had a disease-associated BRCA1 or BRCA2 mutation, was alive with both ovaries intact at the time the woman with whom she was matched underwent prophylactic oophorectomy, and had no history of ovarian cancer at the time of the matched subject's prophylactic oophorectomy.
Using these criteria, we identified 259 eligible subjects who had undergone prophylactic oophorectomy and 292 eligible controls. Three hundred twenty-five subjects (59 percent) were related to at least one other person in the sample. The relatedness of 49 subjects (9 percent) was unknown for various reasons, and they were assumed to be unrelated to any other subject.
Study of Breast-Cancer Risk
The criteria for choosing subjects and matched controls for the group studied to determine breast-cancer risk were identical to those for the group studied to determine ovarian-cancer risk, except that subjects who had undergone prophylactic oophorectomy were excluded if they had previously undergone mastectomy or had a history of breast cancer (including carcinoma in situ) at the time of the prophylactic oophorectomy. Controls were excluded if they had undergone prophylactic oophorectomy or had a history of breast cancer at the time of the matched subject's prophylactic oophorectomy. Using these criteria, we identified 99 subjects who had undergone prophylactic mastectomy and 142 controls.
Data Collection
Enrollment and follow-up at each center were undertaken without regard to surgical status. Information on vital status and the occurrence of cancer was obtained from medical records, telephone interviews, self-administered questionnaires, or a combination of these. For women who had died since their entry into the study, we reviewed medical records and family-history reports to establish the presence or absence of cancer and to verify that they had died. Self-reported reproductive histories and histories of various types of exposure, including hormone use, smoking, and alcohol consumption, were obtained by questionnaire. Occurrences of cancer after surgery were verified by a review of medical records, operative notes, pathology reports, or a combination of these.
Statistical Analysis
Cox proportional-hazards models were used to estimate differences in the incidence of cancer according to whether the woman had undergone prophylactic oophorectomy, with use of Stata software (release 6). A robust variance–covariance estimation method15 was used to correct for nonindependence of observations among related subjects. Subjects who had undergone prophylactic oophorectomy and controls were followed from the date of the subject's prophylactic oophorectomy until the occurrence of the first cancer or until censoring. A diagnosis of cancer derived from the coelomic epithelium (in the ovary or peritoneum) was the primary end point in the group studied to determine the risk of ovarian cancer. Observations were censored as of the date when a subject died or was lost to follow-up, or the date of last contact if neither of these events occurred. In the group studied to determine the risk of breast cancer, the primary end point was the first diagnosis of an invasive breast cancer or a ductal carcinoma in situ. Observations were censored as of the date on which the subject received a diagnosis of ovarian cancer or primary peritoneal carcinoma, underwent prophylactic mastectomy, died, or was lost to follow-up, or the date of last contact if none of these events occurred.
Results
Ovarian Cancer
Subjects who underwent prophylactic oophorectomy and controls were matched with respect to BRCA1 and BRCA2 status, year of birth, age at the time the subject underwent prophylactic oophorectomy, and the center where the surgery was performed. Subjects who underwent prophylactic oophorectomy were significantly more likely than controls to have received hormone-replacement therapy (47.9 percent vs. 19.9 percent, P<0.001), which is prescribed for symptoms of menopause after oophorectomy (Table 1Table 1
Characteristics of the Group Studied to Determine the Risk of Ovarian Cancer.).Of 259 subjects who underwent prophylactic oophorectomy, 8 (3.1 percent) received a diagnosis of ovarian cancer or papillary serous peritoneal cancer at or after oophorectomy, as compared with 58 of 292 controls (19.9 percent) (Table 1). Of the eight cancers in the subjects who underwent prophylactic oophorectomy, six were stage I ovarian cancers that were diagnosed at the time of surgery. Two cases of papillary serous peritoneal cancer were diagnosed 3.8 and 8.6 years after surgery. Neither breast nor ovarian cancer developed in 185 of the 259 subjects who underwent prophylactic oophorectomy (71.4 percent) during follow-up, as compared with 153 of 292 controls (52.4 percent, P<0.001). The average length of follow-up after the subject underwent prophylactic oophorectomy was 8.2 years for those undergoing surgery and 8.8 years for the controls (P=0.54). One hundred thirty-six subjects who underwent prophylactic oophorectomy (52.5 percent) and 124 controls (42.5 percent) were followed for at least five years after the surgery in the subject in the oophorectomy group. The hazard ratio for cancer of the coelomic epithelium after prophylactic oophorectomy was 0.04 (95 percent confidence interval, 0.01 to 0.16) (Table 2Table 2
Effect of Prophylactic Oophorectomy on the Risk of Ovarian and Breast Cancer, According to Selected Variables.).To test whether the point estimate of risk reduction was biased by the use of the date of ascertainment rather than the date of genetic testing, we performed analyses in which the follow-up time was determined from the date of genetic testing to the date of diagnosis of ovarian cancer or censoring in the 450 subjects for whom the date of genetic testing was known. Prophylactic oophorectomy occurred five or more years before testing in 203 women (45 percent), one to five years before testing in 116 women (26 percent), within one year before or after testing in 91 women (20 percent), and one or more years after testing in 40 women (9 percent). This analysis produced a hazard ratio of 0.02 (95 percent confidence interval, 0.01 to 0.14), which was nearly identical to that found when the follow-up time was calculated from the date of surgery.
The pathology records of the two women in whom papillary serous peritoneal cancer developed showed no evidence of ovarian cancer at the time of prophylactic oophorectomy. The time from oophorectomy to the diagnosis of papillary serous peritoneal cancer was 3.8 years in the case of one woman and 8.6 years in the other. No cases of papillary serous peritoneal cancer were diagnosed in controls with intact ovaries.
All six women in whom ovarian cancer was diagnosed at the time of prophylactic oophorectomy had stage I cancers. Among 37 control women who had ovarian cancer for which the stage was known, 11 percent had stage I cancer, 16 percent had stage II, 65 percent had stage III, and 9 percent had stage IV.
Breast Cancer
In the subgroup of 241 subjects in which the incidence of breast cancer was studied, those who underwent prophylactic oophorectomy were followed for an average of 10.7 years after surgery, and the controls were followed for an average of 11.9 years after the time of the matched subject's prophylactic oophorectomy (Table 3Table 3
Characteristics of the Group Studied to Determine the Risk of Breast Cancer.). The length of follow-up was at least five years for 51 of 99 subjects who underwent oophorectomy (51.5 percent) and for 70 of 142 controls (49.3 percent). There were no statistically significant differences between subjects and controls in mean follow-up time, parity, age at delivery of a first live-born child, and age at menarche. There were statistically significant differences between surgical subjects and controls in the rate of oral-contraceptive use (78.8 percent vs. 65.5 percent, P=0.02), the rate of use of hormone-replacement therapy (75.8 percent vs. 21.8 percent, P<0.001), and the number of subjects with censored observations (78.8 percent vs. 45.1 percent, P<0.001).Twenty-one of 99 subjects who underwent prophylactic oophorectomy (21.2 percent) and 60 of 142 controls (42.3 percent) received a diagnosis of breast cancer after the time of the surgical subject's prophylactic oophorectomy (hazard ratio, 0.47; 95 percent confidence interval, 0.29 to 0.77) (Table 2). The subjects who underwent prophylactic oophorectomy were significantly older than the controls at the time of diagnosis (52.5 vs. 46.7 years, P=0.03). The mean time to the diagnosis of breast cancer after prophylactic oophorectomy was 11.4 years for subjects who underwent prophylactic oophorectomy and 8.0 years for controls (P=0.09). Only the first primary breast cancer was considered in our risk-reduction analyses, but a second primary breast cancer developed in five subjects. These results confirm our previous report10 that the risk of breast cancer is substantially reduced after prophylactic oophorectomy.
Discussion
In this group of subjects, bilateral prophylactic oophorectomy reduced the risk of cancer of the coelomic epithelium associated with BRCA1 or BRCA2 mutations by 96 percent and the risk of breast cancer by 53 percent. When the upper bound of the 95 percent confidence interval of the hazard ratio was taken as a conservative estimate, prophylactic oophorectomy reduced the risk of cancer of the coelomic epithelium associated with BRCA1 or BRCA2 mutations by approximately 85 percent and the risk of breast cancer by approximately 25 percent.
Struewing et al.9 reported the results of prophylactic oophorectomy in an analysis of 12 large families with a strong history of breast and ovarian cancer, but without information on BRCA1 or BRCA2 mutation status. Two cases of intraabdominal carcinomatosis were noted after prophylactic oophorectomy in 28 women who were first-degree relatives of patients with ovarian cancer, as compared with eight cases of ovarian cancer in 346 women who were first-degree relatives of patients with ovarian cancer and who had not undergone oophorectomy. These results were suggestive of a protective effect of oophorectomy, but the sample was not large enough to demonstrate a statistically significant effect of prophylactic oophorectomy on the risk of ovarian cancer.
In our study, six women were found to have ovarian cancer at the time of prophylactic oophorectomy, all of whom had stage I disease. Since only 11 percent of ovarian cancers in the control women were stage I, prophylactic oophorectomy may aid in the identification of early-stage, curable ovarian cancer in women with BRCA1 or BRCA2 mutations.
Our study provides some information about the timing of prophylactic oophorectomy relative to the childbearing years. The mean age at the diagnosis of ovarian cancer in our entire data set (including women who were not part of the present study) was 50.8 years (range, 30 to 73 years); this finding supports the practice of performing prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations as soon as feasible after childbearing is completed. Very early prophylactic oophorectomy is probably not required to prevent ovarian cancer in most women with BRCA1 or BRCA2 mutations.
The primary negative consequence of prophylactic oophorectomy in premenopausal women is premature menopause, which may be associated with increased risks of osteoporosis and cardiovascular disease.16,17 Hot flashes, vaginal dryness, sexual dysfunction, sleep disturbances, and cognitive changes associated with menopause may affect the quality of life. However, the risk is balanced by the morbidity and mortality associated with breast and ovarian cancer in carriers of BRCA1 or BRCA2 mutations, and these symptoms may be managed by hormonal or nonhormonal medications.
Surveillance has not been shown to reduce the proportion of ovarian cancers diagnosed in late stages or to affect mortality, which is estimated at 80 percent at five years for stage III disease. Oral-contraceptive use was associated with decreased ovarian-cancer risk in one study,18 but not in another.19 Because of these conflicting reports, recommending the use of oral contraceptives to reduce the risk of ovarian cancer is problematic. Tubal ligation may also reduce ovarian-cancer risk in carriers of BRCA1 (but not the BRCA2) mutations,20 but its reported efficacy is not nearly as great as that of prophylactic oophorectomy.
There are a number of limitations to this study. The widespread use of prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations would have made a randomized trial — the ideal type of study — difficult to perform. A prospective cohort design would also be preferred, but it would limit the availability of results for years. Our matched study design corrects for many of the limitations of a retrospective cohort design. In addition, the present data support the common recommendation that women with BRCA1 or BRCA2 mutations should undergo prophylactic oophorectomy once they have completed childbearing.
On the basis of the results of our study, we advocate prophylactic oophorectomy to reduce the risk of ovarian and breast cancer in women with BRCA1 or BRCA2 mutations. In deciding whether to undergo the procedure, a woman should take into account how long she wishes to maintain fertility, and she should receive counseling about the risks and benefits of prophylactic oophorectomy. The decision should also be made with the knowledge that current surveillance regimens have not been shown to affect the incidence of late-stage ovarian cancer. Although opinion is divided on the use of hormone-replacement therapy after prophylactic oophorectomy, the decision to use estrogens should be based on a consideration of symptoms that affect future health and the quality of life. Some centers routinely recommend hormone-replacement therapy after prophylactic oophorectomy until the age of 50 years, and many women consider prophylactic oophorectomy unacceptable without this option.
Supported by grants from the Public Health Service (R01-CA83855, to Dr. Rebbeck; CA57601, to Dr. Weber; and CA74415, to Dr. Neuhausen), the University of Pennsylvania Cancer Center (to Drs. Rebbeck and Weber), the Breast Cancer Research Foundation (to Dr. Weber), the Dana–Farber Women's Cancers Program (to Dr. Garber), the Department of Defense (DAMD-17-96-I-6088, to Dr. Daly; and DAMD-17-94-J-4340 and DAMD-17-97-I-7112, to Dr. Lynch), the Utah Cancer registry (funded by Public Health Service grant NO1-CN-6700) and the Utah State Department of Health, and the Nebraska State Cancer and Smoking-Related Diseases Research Program (LB595, to Dr. Lynch).
Source Information
From the Center for Clinical Epidemiology and Biostatistics (T.R.R.), Cancer Center (T.R.R., B.L.W.), and Abramson Family Cancer Institute (B.L.W.), University of Pennsylvania School of Medicine, Philadelphia; Creighton University, Omaha, Nebr. (H.T.L.); the Division of Genetic Epidemiology, University of Utah, Salt Lake City (S.L.N.); Women's College Hospital, Toronto (S.A.N.); the Netherlands Cancer Institute, Amsterdam (L.V.); Dana–Farber Cancer Institute, Boston (J.E.G.); St. Mary's Hospital, Manchester, United Kingdom (G.E.); Lombardi Cancer Center, Georgetown University, Washington, D.C. (C.I.); Fox Chase Cancer Center, Philadelphia (M.B.D.); Yale University, New Haven, Conn. (E.M.); and University of Chicago, Chicago (O.I.O.).
Address reprint requests to Dr. Rebbeck at the University of Pennsylvania School of Medicine, 904 Blockley Hall, 423 Guardian Dr., Philadelphia, PA 19104-6021, or at trebbeck@cceb.med.upenn.edu.
The members of the Prevention and Observation of Surgical End Points (PROSE) Study Group are listed in the Appendix.
Appendix
The following investigators were members of the PROSE Study Group: University of Pennsylvania — J. Coyne, C. Punzalan, T. Rebbeck, and B. Weber; Creighton University — C. Snyder, H.T. Lynch, and P. Watson; Dana–Farber Cancer Institute — J.E. Garber and H. Gray; Fox Chase Cancer Center — J. Costalas and M.B. Daly; Georgetown University — A. Dialino-Felix, C. Isaacs, and A. Pinto; Netherlands Cancer Institute — M. van Beurden, H. Klaren, and L. van't Veer; Royal Marsden Hospital — R. Eeles and K. Bishop; St. Mary's Hospital — G. Evans and A. Shenton; University of Chicago — S. Cummings, O. Olopade, and M. Roark; University of Utah — L. Cannon-Albright, S.L. Neuhausen, and L. Steele; Women's College Hospital — S.A. Narod and K. Metcalfe; and Yale University — E. Matloff.
- References
References
1
Ford D ,Easton DF ,Stratton M , et al. Genetic heterogeneity and penetrance analysis of the BRCA1 and BRCA2 genes in breast cancer families. Am J Hum Genet 1998;62:676-689
CrossRef | Web of Science | Medline2
Struewing JP ,Hartge P ,Wacholder S , et al. The risk of cancer associated with specific mutations of BRCA1 and BRCA2 among Ashkenazi Jews. N Engl J Med 1997;336:1401-1408
Full Text | Web of Science | Medline3
Easton DF ,Narod SA ,Ford D ,Steel M . The genetic epidemiology of BRCA1. Lancet 1994;344:761-761
CrossRef | Web of Science | Medline4
Burke W ,Daly M ,Garber J , et al. Recommendations for follow-up care of individuals with an inherited predisposition to cancer. II. BRCA1 and BRCA2. JAMA 1998;277:997-1003
CrossRef | Web of Science5
Fromm GL ,Gershenson DM ,Silva EG . Papillary serous carcinoma of the peritoneum. Obstet Gynecol 1990;75:89-95
Web of Science | Medline6
Zhou J ,Iwasa Y ,Konishi I , et al. Papillary serous carcinoma of the peritoneum in women: a clinicopathologic and immunohistochemical study. Cancer 1995;76:429-436
CrossRef | Web of Science | Medline7
Eltabbakh GH ,Piver MS . Extraovarian primary peritoneal carcinoma. Oncology 1998;12:813-819
Web of Science | Medline8
Piver MS ,Jishi MF ,Tsukada Y ,Nava G . Primary peritoneal carcinoma after prophylactic oophorectomy in women with a family history of ovarian cancer: a report of the Gilda Radner Family Ovarian Cancer Registry. Cancer 1993;71:2751-2755
CrossRef | Web of Science | Medline9
Struewing JP, Watson P, Easton DF, Ponder BAJ, Lynch HT, Tucker MA. Prophylactic oophorectomy in inherited breast/ovarian cancer families. In: Hereditary breast, ovarian, and colon cancer. Journal of the National Cancer Institute monographs. No. 17. Bethesda, Md.: National Cancer Institute, 1995:33-6. (NIH publication no. 94-03837.)
10
Rebbeck TR ,Levin AM ,Eisen A , et al. Breast cancer risk after bilateral prophylactic oophorectomy in BRCA1 mutation carriers. J Natl Cancer Inst 1999;91:1475-1479
CrossRef | Web of Science | Medline11
Brinton LA ,Schairer C ,Hoover RN ,Fraumeni JF Jr . Menstrual factors and risk of breast cancer. Cancer Invest 1988;6:245-254
CrossRef | Web of Science | Medline12
Meijer WJ ,van Lindert AC . Prophylactic oophorectomy. Eur J Obstet Gynecol Reprod Biol 1992;47:59-65
CrossRef | Web of Science | Medline13
Parazzini F ,Braga C ,LaVecchia C ,Negri E ,Acerboni S ,Franceschi S . Hysterectomy, oophorectomy in premenopause, and risk of breast cancer. Obstet Gynecol 1997;90:453-456
CrossRef | Web of Science | Medline14
Schairer C ,Persson I ,Falkeborn M ,Naessen T ,Troisi R ,Brinton LA . Breast cancer risk associated with gynecologic surgery and indications for such surgery. Int J Cancer 1997;70:150-154
CrossRef | Web of Science | Medline15
Lin DY ,Wei LJ . The robust inference for the Cox proportional hazards model. J Am Stat Assoc 1989;84:1074-1078
CrossRef | Web of Science16
Colditz GA ,Willett WC ,Stampfer MJ ,Rosner B ,Speizer FE ,Hennekens CH . Menopause and the risk of coronary heart disease in women. N Engl J Med 1987;316:1105-1110
Full Text | Web of Science | Medline17
Prior JC ,Vigna YM ,Wark JD , et al. Premenopausal ovariectomy-related bone loss: a randomized, double-blind, one-year trial of conjugated estrogen or medroxyprogesterone acetate. J Bone Miner Res 1997;12:1851-1863
CrossRef | Web of Science | Medline18
Narod SA ,Risch H ,Moslehi R , et al. Oral contraceptives and the risk of hereditary ovarian cancer. N Engl J Med 1998;339:424-428
Full Text | Web of Science | Medline19
Modan B ,Hartge P ,Hirsh-Yechezkel G , et al. Parity, oral contraceptives, and the risk of ovarian cancer among carriers and noncarriers of a BRCA1 or BRCA2 mutation. N Engl J Med 2001;345:235-240
Full Text | Web of Science | Medline20
Narod SA ,Sun P ,Ghadirian P , et al. Tubal ligation and risk of ovarian cancer in carriers of BRCA1 or BRCA2 mutations: a case-control study. Lancet 2001;357:1467-1470
CrossRef | Web of Science | Medline
- Citing Articles (405)
Citing Articles
1
David Euhus, Linda Robinson. (2012) Genetic Counseling and Genetic Testing in the Preoperative Evaluation of Breast Cancer Patients. Current Breast Cancer Reports
CrossRef2
Laura L. Holman, Karen H. Lu. (2012) Genetic Risk and Gynecologic Cancers. Hematology/Oncology Clinics of North America 26:1, 13-29
CrossRef3
N. Lynn Henry, Daniel F. Hayes. (2012) Cancer Biomarkers. Molecular Oncology
CrossRef4
D. Gareth Evans. (2012) Genetic predisposition to cancer. Medicine 40:1, 29-33
CrossRef5
Dong Hoon Suh, Kidong Kim, Jae Weon Kim. (2012) Major clinical research advances in gynecologic cancer in 2011. Journal of Gynecologic Oncology 23:1, 53
CrossRef6
L Sidon, S Ingham, T Clancy, R Clayton, A Clarke, E A Jones, F Lalloo, D G R Evans. (2011) Uptake of risk-reducing salpingo-oophorectomy in women carrying a BRCA1 or BRCA2 mutation: evidence for lower uptake in women affected by breast cancer and older women. British Journal of Cancer
CrossRef7
Maria Koutsaki, Apostolos Zaravinos, Demetrios A. Spandidos. (2011) Modern Trends into the Epidemiology and Screening of Ovarian Cancer. Genetic Substrate of the Sporadic Form. Pathology & Oncology Research
CrossRef8
Clara Plusquin, Maxime Fastrez, Jean Vandromme, Serge Rozenberg. (2011) Factors affecting gynaecologists’ decision to perform prophylactic oophorectomy concomitantly with hysterectomy: A Belgian survey. Maturitas 70:4, 391-394
CrossRef9
Soley Bayraktar, Angelica M. Gutierrez-Barrera, Diane Liu, Tunc Tasbas, Ugur Akar, Jennifer K. Litton, E. Lin, Constance T. Albarracin, Funda Meric-Bernstam, Ana M. Gonzalez-Angulo, Gabriel N. Hortobagyi, Banu K. Arun. (2011) Outcome of triple-negative breast cancer in patients with or without deleterious BRCA mutations. Breast Cancer Research and Treatment 130:1, 145-153
CrossRef10
David M. Hyman, Qin Zhou, Angela G. Arnold, Rachel N. Grisham, Alexia Iasonos, Noah D. Kauff, David Spriggs. (2011) Topotecan in patients with BRCA-associated and sporadic platinum-resistant ovarian, fallopian tube, and primary peritoneal cancers. Gynecologic Oncology 123:2, 196-199
CrossRef11
Christina M. Laukaitis. (2011) Genetics for the General Internist. The American Journal of Medicine
CrossRef12
Paul A. Carroll, Carmel Nolan, Roisin Clarke, Michael Farrell, Noreen Gleeson, Terry Boyle, Barbara Dunne, Peter A. Daly, M. John Kennedy, Elizabeth M. Connolly. (2011) Surgical management of an Irish cohort of BRCA-mutation carriers. The Breast 20:5, 419-423
CrossRef13
Ritu Salani, Barbara L. Andersen. (2011) Gynecologic care for breast cancer survivors: Assisting in the transition to wellness. American Journal of Obstetrics and Gynecology
CrossRef14
G. Chêne, I. Raoelfils, A. Cayre, J. Dauplat, Y.-J. Bignon, P. Jaffeux, B. Aublet-Cuvelier, F. Penault-Llorca. (2011) N’oubliez pas les trompes ! Étude morphologique et immunohistochimique des trompes à risque génétique (mutation BRCA). Gynécologie Obstétrique & Fertilité
CrossRef15
Ranjit Manchanda, Ronny Drapkin, Ian Jacobs, Usha Menon. (2011) The role of peritoneal cytology at risk-reducing salpingo-oophorectomy (RRSO) in women at increased risk of familial ovarian/tubal cancer. Gynecologic Oncology
CrossRef16
J. V. Cohen, L. Chiel, L. Boghossian, M. Jones, J. E. Stopfer, J. Powers, T. R. Rebbeck, K. L. Nathanson, S. M. Domchek. (2011) Non-cancer endpoints in BRCA1/2 carriers after risk-reducing salpingo-oophorectomy. Familial Cancer
CrossRef17
Kathleen Y. Yang, Aaron B. Caughey, Sarah E. Little, Michael K. Cheung, Lee-May Chen. (2011) A cost-effectiveness analysis of prophylactic surgery versus gynecologic surveillance for women from hereditary non-polyposis colorectal cancer (HNPCC) Families. Familial Cancer 10:3, 535-543
CrossRef18
Yi Yang, Xiang Li, Tianheng Wang, Patrick D. Kumavor, Andres Aguirre, Kirk K. Shung, Qifa Zhou, Melinda Sanders, Molly Brewer, Quing Zhu. (2011) Integrated optical coherence tomography, ultrasound and photoacoustic imaging for ovarian tissue characterization. Biomedical Optics Express 2:9, 2551
CrossRef19
, B. E. Kiely, M. L. Friedlander, R. L. Milne, L. Stanhope, P. Russell, M. A. Jenkins, P. Weideman, S. A. McLachlan, P. Grant, J. L. Hopper, K. A. Phillips. (2011) Adequacy of risk-reducing gynaecologic surgery in BRCA1 or BRCA2 mutation carriers and other women at high risk of pelvic serous cancer. Familial Cancer 10:3, 505-514
CrossRef20
Karen Lisa Smith, Claudine Isaacs. (2011) Poly(ADP-Ribose) Inhibition: Exploring a New Approach to Breast Cancer Prevention in BRCA1/2 Mutation Carriers. Current Breast Cancer Reports 3:3, 165-171
CrossRef21
David Cibula, Michal Zikan, Ladislav Dusek, Ondrej Majek. (2011) Oral contraceptives and risk of ovarian and breast cancers in BRCA mutation carriers: a meta-analysis. Expert Review of Anticancer Therapy 11:8, 1197-1207
CrossRef22
S. U. Dhar, H. P. Cooper, T. Wang, B. Parks, S. A. Staggs, S. Hilsenbeck, S. E. Plon. (2011) Significant differences among physician specialties in management recommendations of BRCA1 mutation carriers. Breast Cancer Research and Treatment 129:1, 221-227
CrossRef23
Jocelyn S. Chapman, C. Bethan Powell, Jane McLennan, Beth Crawford, Julie Mak, Nicola Stewart, Lee-may Chen. (2011) Surveillance of survivors: Follow-up after risk-reducing salpingo-oophorectomy in BRCA 1/2 mutation carriers. Gynecologic Oncology 122:2, 339-343
CrossRef24
Yi Yang, Nrusingh C. Biswal, Tianheng Wang, Patrick D. Kumavor, Mozafareddin Karimeddini, John Vento, Melinda Sanders, Molly Brewer, Quing Zhu. (2011) Potential role of a hybrid intraoperative probe based on OCT and positron detection for ovarian cancer detection and characterization. Biomedical Optics Express 2:7, 1918
CrossRef25
J Challberg, L Ashcroft, F Lalloo, B Eckersley, R Clayton, P Hopwood, P Selby, A Howell, D G Evans. (2011) Menopausal symptoms and bone health in women undertaking risk reducing bilateral salpingo-oophorectomy: significant bone health issues in those not taking HRT. British Journal of Cancer 105:1, 22-27
CrossRef26
K. Ready, B. K. Arun, K. M. Schmeler, A. Uyei, J. K. Litton, K. H. Lu, C. C. Sun, S. K. Peterson. (2011) Communication of BRCA1 and BRCA2 genetic test results to health care providers following genetic testing at a tertiary care center. Familial Cancer
CrossRef27
Annekathryn Goodman. (2011) Measuring success in ovarian cancer risk reducing strategies. Cancer 117:12, 2588-2589
CrossRef28
Shannon N. Westin, Charlotte C. Sun, Karen H. Lu, Kathleen M. Schmeler, Pamela T. Soliman, Robin A. Lacour, Kristin G. Johnson, Molly S. Daniels, Banu K. Arun, Susan K. Peterson, Diane C. Bodurka. (2011) Satisfaction with ovarian carcinoma risk-reduction strategies among women at high risk for breast and ovarian carcinoma. Cancer 117:12, 2659-2667
CrossRef29
Kathleen M. Schmeler, Charlotte C. Sun, Anais Malpica, Michael T. Deavers, Diane C. Bodurka, David M. Gershenson. (2011) Low-grade serous primary peritoneal carcinoma. Gynecologic Oncology 121:3, 482-486
CrossRef30
Joseph T. Rabban, Amber Mackey, C. Bethan Powell, Beth Crawford, Charles J. Zaloudek, Lee-may Chen. (2011) Correlation of macroscopic and microscopic pathology in risk reducing salpingo-oophorectomy: Implications for intraoperative specimen evaluation. Gynecologic Oncology 121:3, 466-471
CrossRef31
R Manchanda, A Abdelraheim, M Johnson, AN Rosenthal, E Benjamin, C Brunell, M Burnell, L Side, S Gessler, E Saridogan, D Oram, I Jacobs, U Menon. (2011) Outcome of risk-reducing salpingo-oophorectomy in BRCA carriers and women of unknown mutation status. BJOG: An International Journal of Obstetrics & Gynaecology 118:7, 814-824
CrossRef32
Julie O. Culver, Deborah J. MacDonald, Andrea A. Thornton, Sharon R. Sand, Marcia Grant, Deborah J. Bowen, Harry Burke, Nellie Garcia, Kelly A. Metcalfe, Jeffrey N. Weitzel. (2011) Development and Evaluation of a Decision Aid for BRCA Carriers with Breast Cancer. Journal of Genetic Counseling 20:3, 294-307
CrossRef33
Amy S. Clark, Susan M. Domchek. (2011) Clinical Management of Hereditary Breast Cancer Syndromes. Journal of Mammary Gland Biology and Neoplasia 16:1, 17-25
CrossRef34
David M. Euhus. (2011) New insights into the prevention and treatment of familial breast cancer. Journal of Surgical Oncology 103:4, 294-298
CrossRef35
Danielle Campfield Bonadies, Anne Moyer, Ellen T. Matloff. (2011) What I wish I’d known before surgery: BRCA carriers’ perspectives after bilateral salipingo-oophorectomy. Familial Cancer 10:1, 79-85
CrossRef36
Katrien Verhoeven, Philippe DeWilde, Bruce Poppe, Anne Paepe, Geert Crombez. (2011) De relatie tussen genetisch onderzoek, psychologisch welbevinden en medisch handelen Een vragenlijststudie bij vrouwelijke en mannelijke presymptomatische dragers en niet-dragers van een BRCA-genmutatie. Psychologie & gezondheid 2011:1, 12-22
CrossRef37
Kerstin Rhiem, Dolores Foth, Barbara Wappenschmidt, Heidrun Gevensleben, Reinhard Büttner, Uwe Ulrich, Rita K. Schmutzler. (2011) Risk-reducing salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers. Archives of Gynecology and Obstetrics 283:3, 623-627
CrossRef38
Katherine L. Nathanson, Susan M. Domchek. (2011) Therapeutic Approaches for Women Predisposed to Breast Cancer. Annual Review of Medicine 62:1, 295-306
CrossRef39
Victor R. Grann, Priya R. Patel, Judith S. Jacobson, Ellen Warner, Daniel F. Heitjan, Maxine Ashby-Thompson, Dawn L. Hershman, Alfred I. Neugut. (2011) Comparative effectiveness of screening and prevention strategies among BRCA1/2-affected mutation carriers. Breast Cancer Research and Treatment 125:3, 837-847
CrossRef40
Yi Yang, Tianheng Wang, Nrusingh C. Biswal, Xiaohong Wang, Melinda Sanders, Molly Brewer, Quing Zhu. (2011) Optical scattering coefficient estimated by optical coherence tomography correlates with collagen content in ovarian tissue. Journal of Biomedical Optics 16:9, 090504
CrossRef41
A. Paradiso, S. Formenti. (2011) Hereditary breast cancer: clinical features and risk reduction strategies. Annals of Oncology 22:Supplement 1, i31-i36
CrossRef42
Do Hoon Koo, Il Yong Chung, Eunyoung Kang, Sang Ah Han, Sung-Won Kim. (2011) Usage Patterns of Surveillance, Chemoprevention and Risk-Reducing Surgery in Korean BRCA Mutation Carriers: 5 Years of Experience at a Single Institution. Journal of Breast Cancer 14:Suppl 1, S17
CrossRef43
D. Cibula, M. Widschwendter, O. Majek, L. Dusek. (2011) Tubal ligation and the risk of ovarian cancer: review and meta-analysis. Human Reproduction Update 17:1, 55-67
CrossRef44
Marielle AE Nobbenhuis, Elizabeth Bancroft, Eleanor Moskovic, Fiona Lennard, Paul Pharoah, Ian Jacobs, Ann Ward, Desmond PJ Barton, Thomas EJ Ind, John H Shepherd, Jane E Bridges, Martin Gore, Chris Haracopos, Susan Shanley, Audrey Ardern-Jones, Sarah Thomas, Rosalind A Eeles. (2011) Screening for ovarian cancer in women with varying levels of risk, using annual tests, results in high recall for repeat screening tests.. Hereditary Cancer in Clinical Practice 9:1, 11
CrossRef45
Eunyoung Kang, Sue K. Park, Ku Sang Kim, Doo Ho Choi, Seok-Jin Nam, Nam Sun Paik, Jong Won Lee, Min Hyuk Lee, Sung-Won Kim, . (2011) Communication with Family Members about Positive BRCA1/2 Genetic Test Results in Korean Hereditary Breast Cancer Families. Journal of Genetic Medicine 8:2, 105
CrossRef46
Marc D. Schwartz, Claudine Isaacs, Kristi D. Graves, Elizabeth Poggi, Beth N. Peshkin, Christy Gell, Clinton Finch, Scott Kelly, Kathryn L. Taylor, Lauren Perley. (2011) Long-term outcomes of BRCA1/BRCA2 testing: risk reduction and surveillance. Cancern/a-n/a
CrossRef47
Claire Julian-Reynier, Anne-Déborah Bouhnik, Emanuelle Mouret-Fourme, Marion Gauthier-Villars, Pascaline Berthet, Christine Lasset, Jean-Pierre Fricker, Olivier Caron, Paul Gesta, Elisabeth Luporsi, Laurence Faivre, Michel Longy, Laurence Gladieff, Marc Frenay, Héléne Dreyfus, Hagay Sobol, Philippe Vennin, Catherine Nogués. (2010) Time to prophylactic surgery in BRCA1/2 carriers depends on psychological and other characteristics. Genetics in Medicine 12:12, 801-807
CrossRef48
Antonio F. Saad, Wei Hu, Anil K. Sood. (2010) Microenvironment and Pathogenesis of Epithelial Ovarian Cancer. Hormones and Cancer 1:6, 277-290
CrossRef49
Dorina M. Kolk, Geertruida H. Bock, Beike K. Leegte, Michael Schaapveld, Marian J. E. Mourits, Jakob Vries, Annemieke H. Hout, Jan C. Oosterwijk. (2010) Penetrance of breast cancer, ovarian cancer and contralateral breast cancer in BRCA1 and BRCA2 families: high cancer incidence at older age. Breast Cancer Research and Treatment 124:3, 643-651
CrossRef50
Christine Holmberg, Mary Daly, Worta McCaskill-Stevens. (2010) Risk scores and decision making: the anatomy of a decision to reduce breast cancer risk. Journal of Nursing and Healthcare of Chronic Illness 2:4, 271-280
CrossRef51
Leslie S. Bradford, John O. Schorge. (2010) CA125 screening after risk-reducing salpingo-oophorectomy. Menopause1
CrossRef52
Suzanne C. O’Neill, Heiddis B. Valdimarsdottir, Tiffani A. DeMarco, Beth N. Peshkin, Kristi D. Graves, Karen Brown, Karen E. Hurley, Claudine Isaacs, Sharon Hecker, Marc D. Schwartz. (2010) BRCA1/2 test results impact risk management attitudes, intentions, and uptake. Breast Cancer Research and Treatment 124:3, 755-764
CrossRef53
Susan M. Domchek, Tara M. Friebel, Judy E. Garber, Claudine Isaacs, Ellen Matloff, Rosalind Eeles, D. Gareth Evans, Wendy Rubinstein, Christian F. Singer, Stephen Rubin, Henry T. Lynch, Mary B. Daly, Jeffrey Weitzel, Patricia A. Ganz, Gabriella Pichert, Olufunmilayo I. Olopade, Gail Tomlinson, Nadine Tung, Joanne L. Blum, Fergus Couch, Timothy R. Rebbeck. (2010) Occult ovarian cancers identified at risk-reducing salpingo-oophorectomy in a prospective cohort of BRCA1/2 mutation carriers. Breast Cancer Research and Treatment 124:1, 195-203
CrossRef54
Maria Tria Tirona, Rajesh Sehgal, Oscar Ballester. (2010) Prevention of Breast Cancer (Part II): Risk Reduction Strategies. Cancer Investigation 28:10, 1070-1077
CrossRef55
Eitan Amir, Bostjan Seruga, Rosario Serrano, Alberto Ocana. (2010) Targeting DNA repair in breast cancer: A clinical and translational update. Cancer Treatment Reviews 36:7, 557-565
CrossRef56
Arturo Prado, Patricio Andrades, Francisco Parada. (2010) Recent developments in the ability to predict and modify breast cancer risk. Journal of Plastic, Reconstructive & Aesthetic Surgery 63:10, 1581-1587
CrossRef57
John O. Schorge, Susan C. Modesitt, Robert L. Coleman, David E. Cohn, Noah D. Kauff, Linda R. Duska, Thomas J. Herzog. (2010) SGO White Paper on Ovarian Cancer: Etiology, Screening and Surveillance. Gynecologic Oncology 119:1, 7-17
CrossRef58
Anne M. van Altena, Hilda Holtsema, Jan C. Hendriks, Leon F. Massuger, Joanne A. de Hullu. (2010) Cancer antigen 125 level after a bilateral salpingo-oophorectomy. Menopause1
CrossRef59
Ismail Jatoi, John R. Benson, Siong-Seng Liau, Yijun Chen, Robin M. Cisco, Jeffrey A. Norton, Jeffrey F. Moley, Katherine W. Khalifeh, Michael A. Choti. (2010) The Role of Surgery in Cancer Prevention. Current Problems in Surgery 47:10, 750-830
CrossRef60
Pedro F. Escobar, David C. Starks, Amanda Nickles Fader, Matthew Barber, Luis Rojas-Espalliat. (2010) Single-port risk-reducing salpingo-oophorectomy with and without hysterectomy: Surgical outcomes and learning curve analysis. Gynecologic Oncology 119:1, 43-47
CrossRef61
Deborah Hemel, Susan M. Domchek. (2010) Breast Cancer Predisposition Syndromes. Hematology/Oncology Clinics of North America 24:5, 799-814
CrossRef62
Galen Joseph, Mary S. Beattie, Robin Lee, Dejana Braithwaite, Carolina Wilcox, Maya Metrikin, Kate Lamvik, Judith Luce. (2010) Pre-counseling Education for Low Literacy Women at Risk of Hereditary Breast and Ovarian Cancer (HBOC): Patient Experiences Using the Cancer Risk Education Intervention Tool (CREdIT). Journal of Genetic Counseling 19:5, 447-462
CrossRef63
Danielle Vicus, Patricia A. Shaw, Amy Finch, Barry Rosen, Joan Murphy, Susan Armel, Ping Sun, Steven A. Narod. (2010) Risk factors for non-invasive lesions of the fallopian tube in BRCA mutation carriers. Gynecologic Oncology 118:3, 295-298
CrossRef64
Gemma Molyneux, Felipe C. Geyer, Fiona-Ann Magnay, Afshan McCarthy, Howard Kendrick, Rachael Natrajan, Alan MacKay, Anita Grigoriadis, Andrew Tutt, Alan Ashworth, Jorge S. Reis-Filho, Matthew J. Smalley. (2010) BRCA1 Basal-like Breast Cancers Originate from Luminal Epithelial Progenitors and Not from Basal Stem Cells. Cell Stem Cell 7:3, 403-417
CrossRef65
Jonathan S. Berek, Eva Chalas, Mitchell Edelson, David H. Moore, William M. Burke, William A. Cliby, Andrew Berchuck. (2010) Prophylactic and Risk-Reducing Bilateral Salpingo-oophorectomy. Obstetrics & Gynecology 116:3, 733-743
CrossRef66
G. Pichert, C. Jacobs, I. Jacobs, U. Menon, R. Manchanda, M. Johnson, H. Hamed, C. Firth, M. Evison, A. Tutt, L. Silva, C. Langman, L. Izatt. (2010) Novel one-stop multidisciplinary follow-up clinic significantly improves cancer risk management in BRCA1/2 carriers. Familial Cancer 9:3, 313-319
CrossRef67
Kaylene J. Ready, Molly S. Daniels, Charlotte C. Sun, Susan K. Peterson, Hope Northrup, Karen H. Lu. (2010) Obstetrics/Gynecology Residents’ Knowledge of Hereditary Breast and Ovarian Cancer and Lynch Syndrome. Journal of Cancer Education 25:3, 401-404
CrossRef68
X. Wang, V. S. Pankratz, Z. Fredericksen, R. Tarrell, M. Karaus, L. McGuffog, P. D. P. Pharaoh, B. A. J. Ponder, A. M. Dunning, S. Peock, M. Cook, C. Oliver, D. Frost, , O. M. Sinilnikova, D. Stoppa-Lyonnet, S. Mazoyer, C. Houdayer, , F. B. L. Hogervorst, M. J. Hooning, M. J. Ligtenberg, , A. Spurdle, G. Chenevix-Trench, , R. K. Schmutzler, B. Wappenschmidt, C. Engel, A. Meindl, S. M. Domchek, K. L. Nathanson, T. R. Rebbeck, C. F. Singer, D. Gschwantler-Kaulich, C. Dressler, A. Fink, C. I. Szabo, M. Zikan, L. Foretova, K. Claes, G. Thomas, R. N. Hoover, D. J. Hunter, S. J. Chanock, D. F. Easton, A. C. Antoniou, F. J. Couch. (2010) Common variants associated with breast cancer in genome-wide association studies are modifiers of breast cancer risk in BRCA1 and BRCA2 mutation carriers. Human Molecular Genetics 19:14, 2886-2897
CrossRef69
Ava Kwong, Connie H. N. Wong, Catherine Shea, Dacita T. K. Suen, Catherine L. Y. Choi. (2010) Choice of Management of Southern Chinese BRCA Mutation Carriers. World Journal of Surgery 34:7, 1416-1426
CrossRef70
Ellis, Matthew, . (2010) Taxane-Based Chemotherapy for Node-Positive Breast Cancer — Take-Home Lessons. New England Journal of Medicine 362:22, 2122-2124
Full Text71
Nasim Mavaddat, Antonis C. Antoniou, Douglas F. Easton, Montserrat Garcia-Closas. (2010) Genetic susceptibility to breast cancer. Molecular Oncology 4:3, 174-191
CrossRef72
Lisa A. Carey. (2010) Through a Glass Darkly: Advances in Understanding Breast Cancer Biology, 2000-2010. Clinical Breast Cancer 10:3, 188-195
CrossRef73
N. Colombo, M. Peiretti, G. Parma, M. Lapresa, R. Mancari, S. Carinelli, C. Sessa, M. Castiglione, . (2010) Newly diagnosed and relapsed epithelial ovarian carcinoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology 21:Supplement 5, v23-v30
CrossRef74
Mary B Daly. (2010) Oophorectomy as a preventative measure for ovarian cancer. Therapy 7:3, 241-247
CrossRef75
Nancie Petrucelli, Mary B. Daly, Gerald L. Feldman. (2010) Hereditary breast and ovarian cancer due to mutations in BRCA1 and BRCA2. Genetics in Medicine 12:5, 245-259
CrossRef76
Ilana Cass, Ann Walts, Beth Y. Karlan. (2010) Does risk-reducing bilateral salpingo-oophorectomy leave behind residual tube?. Gynecologic Oncology 117:1, 27-31
CrossRef77
A-B Skytte, A-M Gerdes, MK Andersen, L Sunde, K Brøndum-Nielsen, M Waldstrøm, S Kølvraa, D Crüger. (2010) Risk-reducing mastectomy and salpingo-oophorectomy in unaffected BRCA mutation carriers: uptake and timing. Clinical Genetics 77:4, 342-349
CrossRef78
Kaylene Ready, Jennifer K Litton, Banu K Arun. (2010) Clinical application of breast cancer risk assessment models. Future Oncology 6:3, 355-365
CrossRef79
Jane C. Figueiredo, Robert W. Haile, Leslie Bernstein, Kathleen E. Malone, Joan Largent, Bryan Langholz, Charles F. Lynch, Lisbeth Bertelsen, Marinela Capanu, Patrick Concannon, Ake Borg, Anne-Lise Børresen-Dale, Anh Diep, Sharon Teraoka, Therese Torngren, Shanyan Xue, Jonine L. Bernstein. (2010) Oral contraceptives and postmenopausal hormones and risk of contralateral breast cancer among BRCA1 and BRCA2 mutation carriers and noncarriers: the WECARE Study. Breast Cancer Research and Treatment 120:1, 175-183
CrossRef80
William J. Casey, Alanna M. Rebecca, Lewis A. Andres, Randall O. Craft, Anthony A. Smith, Barbara A. Pockaj, Rosanne M. Kho, Paul M. Magtibay. (2010) Safety and Efficacy of Perforator Flap Breast Reconstruction With Combined Intraabdominal Procedures. Annals of Plastic Surgery 64:2, 144-150
CrossRef81
Kathleen M. Schmeler, Molly S. Daniels, Pamela T. Soliman, Russell R. Broaddus, Michael T. Deavers, Thuy M. Vu, George J. Chang, Karen H. Lu. (2010) Primary Peritoneal Cancer After Bilateral Salpingo-Oophorectomy in Two Patients With Lynch Syndrome. Obstetrics & Gynecology 115:Supplement, 432-434
CrossRef82
Helen Hanson, Shirley Hodgson. (2010) Cancer genetics and reproduction. Best Practice & Research Clinical Obstetrics & Gynaecology 24:1, 3-18
CrossRef83
Eunyoung Kang, Sei-Hyun Ahn, Woo-Chul Noh, Dong-Young Noh, Yongsik Jung, Lee Su Kim, Doo Ho Choi, Young Jin Suh, Ku Sang Kim, Jeong Eon Lee, Min Hyuk Lee, Seok-Jin Nam, Byung-In Moon, Byung Ho Son, Jung-Hyun Yang, Cha Kyong Yom, Sung Yong Kim, Sue K. Park, Sung-Won Kim, . (2010) The Change of Practice Patterns of the Hereditary Breast Cancer Management in Korea after the Korean Hereditary Breast Cancer Study. Journal of Breast Cancer 13:4, 418
CrossRef84
Joseph T. Rabban, Robert A. Soslow, Charles Z. Zaloudek. 2010. Immunohistology of the Female Genital Tract. , 690-762.
CrossRef85
Amy L. Gross, Robert J. Kurman, Russell Vang, Ie-Ming Shih, Kala Visvanathan. (2010) Precursor Lesions of High-Grade Serous Ovarian Carcinoma: Morphological and Molecular Characteristics. Journal of Oncology 2010, 1-9
CrossRef86
S. M. Domchek, M. M. Gaudet, J. E. Stopfer, M. H. Fleischaut, J. Powers, N. Kauff, K. Offit, K. L. Nathanson, M. Robson. (2010) Breast cancer risks in individuals testing negative for a known family mutation in BRCA1 or BRCA2. Breast Cancer Research and Treatment 119:2, 409-414
CrossRef87
Goran Malenkovic, Tihomir Dugandzija, Aljosa Mandic, Marija Velaga, Olivera Tesic, Marina Popovic. (2010) Linear trend in patients with ovarian cancer in period 2001-2008 at Oncology Institute of Vojvodina. Medicinski pregled 63:9-10, 607-610
CrossRef88
Wendy McKinnon, Kimberly C. Banks, Joan Skelly, Wendy Kohlmann, Robin Bennett, Kristen Shannon, Joy Larson-Haidle, Taka Ashakaga, Jeffrey N. Weitzel, Marie Wood. (2009) Survey of unaffected BRCA and mismatch repair (MMR) mutation positive individuals. Familial Cancer 8:4, 363-369
CrossRef89
P. Shah, M. Rosen, J. Stopfer, J. Siegfried, R. Kaltman, B. Mason, K. Armstrong, K. L. Nathanson, M. Schnall, S. M. Domchek. (2009) Prospective study of breast MRI in BRCA1 and BRCA2 mutation carriers: effect of mutation status on cancer incidence. Breast Cancer Research and Treatment 118:3, 539-546
CrossRef90
Analisa DiFeo, Goutham Narla, John A. Martignetti. (2009) Emerging Roles of Kruppel-Like Factor 6 and Kruppel-Like Factor 6 Splice Variant 1 in Ovarian Cancer Progression and Treatment. Mount Sinai Journal of Medicine: A Journal of Translational and Personalized Medicine 76:6, 557-566
CrossRef91
Carlos A. Garcia-Etienne, Monica Barile, Oreste D. Gentilini, Edoardo Botteri, Nicole Rotmensz, Andrea Sagona, Gabriel Farante, Viviana Galimberti, Alberto Luini, Paolo Veronesi, Bernardo Bonanni. (2009) Breast-Conserving Surgery in BRCA1/2 Mutation Carriers: Are We Approaching an Answer?. Annals of Surgical Oncology 16:12, 3380-3387
CrossRef92
S. Lax. (2009) Seröse Genitalkarzinome. Der Pathologe 30:S2, 210-216
CrossRef93
Joseph T. Rabban, Ellen Krasik, Lee-May Chen, Catherine B. Powell, Beth Crawford, Charles J. Zaloudek. (2009) Multistep Level Sections to Detect Occult Fallopian Tube Carcinoma in Risk-reducing Salpingo-oophorectomies From Women With BRCA Mutations. The American Journal of Surgical Pathology 33:12, 1878-1885
CrossRef94
Beth Y. Karlan, Thomas P. McNally, Michael J. Birrer. (2009) Debate: Routine Screening for Patients at High Risk for Ovarian Cancer. Clinical Ovarian Cancer 2:2, 83-89
CrossRef95
D Gareth R Evans, Richard Clayton, Paul Donnai, Andrew Shenton, Fiona Lalloo. (2009) Risk-reducing surgery for ovarian cancer: outcomes in 300 surgeries suggest a low peritoneal primary risk. European Journal of Human Genetics 17:11, 1381-1385
CrossRef96
Thomas P. McNally, Michael J. Birrer. (2009) CON: Patients at High Risk for Ovarian Cancer Should Not Undergo Routine Screening. Clinical Ovarian Cancer 2:2, 86-89
CrossRef97
Susan M. Domchek, Roger A. Greenberg. (2009) Breast cancer gene variants: separating the harmful from the harmless. Journal of Clinical Investigation 119:10, 2895-2897
CrossRef98
Ram Eitan, Rachel Michaelson-Cohen, Hanoch Levavi, Uziel Beller. (2009) The Counseling and Management of Young Healthy BRCA Mutation Carriers. International Journal of Gynecological Cancer 19:7, 1156-1159
CrossRef99
Bryan T Hennessy, Robert L Coleman, Maurie Markman. (2009) Ovarian cancer. The Lancet 374:9698, 1371-1382
CrossRef100
Jurgen Mulsow, James Lee, Cathriona Dempsey, Jane Rothwell, James G. Geraghty. (2009) Establishing a Family Risk Assessment Clinic for Breast Cancer. The Breast Journal 15, S33-S38
CrossRef101
Angela G. Arnold, Noah D. Kauff. (2009) Prophylactic oophorectomy may differentially reduce breast cancer risk in women with BRCA1 versus BRCA2 mutations. Current Breast Cancer Reports 1:3, 157-161
CrossRef102
Henry T. Lynch, Carrie L. Snyder, Jane F. Lynch, Sumedha Ghate, Steven A. Narod, Gordon Gong. (2009) Family Information Service Participation Increases the Rates of Mutation Testing Among Members of Families with BRCA1/2 Mutations. The Breast Journal 15, S20-S24
CrossRef103
Carrie L. Snyder, Jane F. Lynch, Henry T. Lynch. (2009) Genetic Counseling and the Advanced Practice Oncology Nursing Role in a Hereditary Cancer Prevention Clinic: Hereditary Breast Cancer Focus (Part I). The Breast Journal 15, S2-S10
CrossRef104
Andrea D. Forman, Michael J. Hall. (2009) Influence of Race/Ethnicity on Genetic Counseling and Testing for Hereditary Breast and Ovarian Cancer. The Breast Journal 15, S56-S62
CrossRef105
Larissa A. Korde, Shahinaz M. Gadalla. (2009) Cancer Risk Assessment for the Primary Care Physician. Primary Care: Clinics in Office Practice 36:3, 471-488
CrossRef106
Edibaldo Silva. (2009) Targeted Tailored Management of the Breast Cancer Patient at Risk for Harboring a Germline Mutation-Current Trends Affecting the Selection of Patients Considering Surgical Prophylaxis for Breast Cancer. The Breast Journal 15, S76-S80
CrossRef107
Susan M. Domchek. (2009) Refining BRCA1 and BRCA2 penetrance estimates in the clinic. Current Breast Cancer Reports 1:3, 127-130
CrossRef108
Sheryl G.A. Gabram, Teri Dougherty, Kathy S. Albain, Kimberly Klein, Patricia Mumby, Kit Lee, Kathy Yao, Bhuma Krishnamachari, Catheryn J. Salibay, Mary Jo Lund. (2009) Assessing Breast Cancer Risk and Providing Treatment Recommendations: Immediate Impact of an Educational Session. The Breast Journal 15, S39-S45
CrossRef109
Jane C. Figueiredo, Robert W. Haile, Jonine L. Bernstein. (2009) Oral contraceptives and breast cancer risk in BRCA1 and BRCA2 mutation carriers. Current Breast Cancer Reports 1:3, 139-147
CrossRef110
Wendy S. Rubinstein, Hongmei Jiang, Lisa Dellefave, Alfred W. Rademaker. (2009) Cost-effectiveness of population-based BRCA1/2 testing and ovarian cancer prevention for Ashkenazi Jews: A call for dialogue. Genetics in Medicine 11:9, 629-639
CrossRef111
Elgene Lim, François Vaillant, Di Wu, Natasha C Forrest, Bhupinder Pal, Adam H Hart, Marie-Liesse Asselin-Labat, David E Gyorki, Teresa Ward, Audrey Partanen, Frank Feleppa, Lily I Huschtscha, Heather J Thorne, Stephen B Fox, Max Yan, Juliet D French, Melissa A Brown, Gordon K Smyth, Jane E Visvader, Geoffrey J Lindeman. (2009) Aberrant luminal progenitors as the candidate target population for basal tumor development in BRCA1 mutation carriers. Nature Medicine 15:8, 907-913
CrossRef112
Joseph T. Rabban, Michael Barnes, Lee-May Chen, Catherine B. Powell, Beth Crawford, Charles J. Zaloudek. (2009) Ovarian Pathology in Risk-reducing Salpingo-oophorectomies From Women With BRCA Mutations, Emphasizing the Differential Diagnosis of Occult Primary and Metastatic Carcinoma. The American Journal of Surgical Pathology 33:8, 1125-1136
CrossRef113
M Widschwendter, H Lichtenberg-Frate, G Hasenbrink, S Schwarzer, A Dawnay, A Lam, U Menon, S Apostolidou, E Raum, C Stegmaier, I J Jacobs, H Brenner. (2009) Serum oestrogen receptor α and β bioactivity are independently associated with breast cancer: a proof of principle study. British Journal of Cancer 101:1, 160-165
CrossRef114
Ritu Salani, Floor J Backes, Larry J Copeland. (2009) Overview of epithelial ovarian cancer and updates in management strategies. Expert Review of Obstetrics & Gynecology 4:4, 383-399
CrossRef115
Jane E. Hirst, Gregory B. Gard, Kirsty McIllroy, David Nevell, Michael Field. (2009) High Rates of Occult Fallopian Tube Cancer Diagnosed at Prophylactic Bilateral Salpingo-Oophorectomy. International Journal of Gynecological Cancer 19:5, 826-829
CrossRef116
2009. Prophylactic Mastectomy. , 200-209.
CrossRef117
Michael J. Hall, Julia E. Reid, Lynn A. Burbidge, Dmitry Pruss, Amie M. Deffenbaugh, Cynthia Frye, Richard J. Wenstrup, Brian E. Ward, Thomas A. Scholl, Walter W. Noll. (2009) BRCA1 and BRCA2 mutations in women of different ethnicities undergoing testing for hereditary breast-ovarian cancer. Cancer 115:10, 2222-2233
CrossRef118
Maite Cusidó, Clara Colomé, Ignacio Rodríguez, Rafael Fábregas. (2009) Consulta de riesgo oncológico. Selección de grupos de riesgo y resultados. Medicina Clínica 132:20, 779-782
CrossRef119
, M. Graeser, K. Bosse, M. Brosig, C. Engel, R. K. Schmutzler. (2009) Association of hormone receptor status with grading, age of onset, and tumor size in BRCA1-associated breast cancer. Virchows Archiv 454:5, 519-524
CrossRef120
Henry T. Lynch, Murray Joseph Casey, Carrie L. Snyder, Chhanda Bewtra, Jane F. Lynch, Matthew Butts, Andrew K. Godwin. (2009) Hereditary ovarian carcinoma: Heterogeneity, molecular genetics, pathology, and management. Molecular Oncology 3:2, 97-137
CrossRef121
(2009) Hereditary Breast and Ovarian Cancer Syndrome. Gynecologic Oncology 113:1, 6-11
CrossRef122
C. A. Gabriel, J. Tigges-Cardwell, J. Stopfer, J. Erlichman, K. Nathanson, S. M. Domchek. (2009) Use of total abdominal hysterectomy and hormone replacement therapy in BRCA1 and BRCA2 mutation carriers undergoing risk-reducing salpingo-oophorectomy. Familial Cancer 8:1, 23-28
CrossRef123
Carolyn Y. Fang, Carol Cherry, Karthik Devarajan, Tianyu Li, John Malick, Mary B. Daly. (2009) A prospective study of quality of life among women undergoing risk-reducing salpingo-oophorectomy versus gynecologic screening for ovarian cancer. Gynecologic Oncology 112:3, 594-600
CrossRef124
Nienke M. van der Velde, Marian J.E. Mourits, Henriëtte J.G. Arts, Jacob de Vries, Beike K. Leegte, Grieteke Dijkhuis, Jan C. Oosterwijk, Geertruida H. de Bock. (2009) Time to stop ovarian cancer screening in BRCA1/2 mutation carriers?. International Journal of Cancer 124:4, 919-923
CrossRef125
E.J. Majdak-Paredes, F. Fatah. (2009) Hereditary breast cancer syndromes and clinical implications. Journal of Plastic, Reconstructive & Aesthetic Surgery 62:2, 181-189
CrossRef126
Ranjit Manchanda, Usha Menon, Rachel Michaelson-Cohen, Uziel Beller, Ian Jacobs. (2009) Hereditary non-polyposis colorectal cancer or Lynch syndrome: the gynaecological perspective. Current Opinion in Obstetrics and Gynecology 21:1, 31-38
CrossRef127
Ashok R. Venkitaraman. (2009) Linking the Cellular Functions of BRCA Genes to Cancer Pathogenesis and Treatment. Annual Review of Pathology: Mechanisms of Disease 4:1, 461-487
CrossRef128
Mary S. Beattie, Beth Crawford, Feng Lin, Eric Vittinghoff, John Ziegler. (2009) Uptake, Time Course, and Predictors of Risk-Reducing Surgeries in BRCA Carriers. Genetic Testing and Molecular Biomarkers 13:1, 51-56
CrossRef129
T. R. Rebbeck, N. D. Kauff, S. M. Domchek. (2009) Meta-analysis of Risk Reduction Estimates Associated With Risk-Reducing Salpingo-oophorectomy in BRCA1 or BRCA2 Mutation Carriers. JNCI Journal of the National Cancer Institute 101:2, 80-87
CrossRef130
Mary S. Beattie, Beth Crawford, Feng Lin, Eric Vittinghoff, John Ziegler. (2009) Uptake, Time Course, and Predictors of Risk-Reducing Surgeries in BRCA Carriers. Genetic Testing 0:0, 090108090224061
CrossRef131
Kelly A Metcalfe. (2009) Oophorectomy for breast cancer prevention in women with BRCA1 or BRCA2 mutations. Women's Health 5:1, 63-68
CrossRef132
Ellen T. Matloff, Rachel E. Barnett, Sharon L. Bober. (2009) Unraveling the Next Chapter. The Cancer Journal 15:1, 15-18
CrossRef133
Antonio Russo, Valentina Calò, Loredana Bruno, Sergio Rizzo, Viviana Bazan, Gaetana Di Fede. (2009) Hereditary ovarian cancer. Critical Reviews in Oncology/Hematology 69:1, 28-44
CrossRef134
Joseph T. Rabban, Beth Crawford, Lee-May Chen, Catherine B. Powell, Charles J. Zaloudek. (2009) Transitional Cell Metaplasia of Fallopian Tube Fimbriae. The American Journal of Surgical Pathology 33:1, 111-119
CrossRef135
Sung-Won Kim. (2009) Korean Hereditary Breast Cancer. Journal of the Korean Medical Association 52:10, 952
CrossRef136
Michael S. Sabel. 2009. Identifying and Managing the High-Risk Patient. , 101-122.
CrossRef137
Robert L. Barbieri. 2009. The Breast. , 235-248.
CrossRef138
Gareth Evans. 2009. Risk assessment and management. , 327-337.
CrossRef139
Heather J. Hether, Grace C. Huang, Vicki Beck, Sheila T. Murphy, Thomas W. Valente. (2008) Entertainment-Education in a Media-Saturated Environment: Examining the Impact of Single and Multiple Exposures to Breast Cancer Storylines on Two Popular Medical Dramas. Journal of Health Communication 13:8, 808-823
CrossRef140
Nina Hallowell. (2008) Encounters with medical professionals: a crisis of trust or matter of respect?. Medicine, Health Care and Philosophy 11:4, 427-437
CrossRef141
Ioannis M. Matalliotakis, Hakan Cakmak, Neal Mahutte, Anastasia G. Goumenou, Georgios Koumantakis, Aydin Arici. (2008) The familial risk of breast cancer in women with endometriosis from Yale series. Surgical Oncology 17:4, 289-293
CrossRef142
Beverly Mangerich, Jaynelle F. Stichler. (2008) Breast and Ovarian Cancer: A New Model For Educating Women. Nursing for Women's Health 12:6, 490-499
CrossRef143
Jan T. Lowery, Tim Byers, Lisen Axell, Lisa Ku, Jillian Jacobellis. (2008) The impact of direct-to-consumer marketing of cancer genetic testing on women according to their genetic risk. Genetics in Medicine 10:12, 888-894
CrossRef144
Sarah Fuller, Fabienne Liebens, Birgit Carly, Anne Pastijn, Serge Rozenberg. (2008) Breast Cancer Prevention in BRCA1/2 Mutation Carriers: A Qualitative Review. The Breast Journal 14:6, 603-604
CrossRef145
M. Kiechle, N. Arnold, B. Schlegelberger. (2008) Hereditäres Ovarialkarzinom. Der Onkologe 14:11, 1120-1129
CrossRef146
B. Schlehe, R. Schmutzler. (2008) Hereditäres Mammakarzinom. Der Chirurg 79:11, 1047-1054
CrossRef147
Jacques De Grève, Erica Sermijn, Sylvia De Brakeleer, Zhuo Ren, Erik Teugels. (2008) Hereditary breast cancer: from bench to bedside. Current Opinion in Oncology 20:6, 605-613
CrossRef148
John V. Brown, Howard D. Epstein, Julie N. Mattison, John P. Micha, Mark A. Rettenmaier, Bram H. Goldstein. (2008) Occult Fallopian Tube Cancer in a Patient with BRCA1 Breast Cancer. Journal of Minimally Invasive Gynecology 15:6, 749-751
CrossRef149
Allison Werner-Lin. (2008) Beating the Biological Clock: The Compressed Family Life Cycle of Young Women with BRCA Gene Alterations. Social Work in Health Care 47:4, 416-437
CrossRef150
Dawn C. Allain. (2008) Genetic Counseling and Testing for Common Hereditary Breast Cancer Syndromes. The Journal of Molecular Diagnostics 10:5, 383-395
CrossRef151
Ruquaya Mir, V P Singh, Praveen Sodhi. (2008) Breast Cancer Risk Assessment and Risk Reduction. Apollo Medicine 5:3, 143-149
CrossRef152
Katrina J. Lowstuter, Sharon Sand, Kathleen R. Blazer, Deborah J. MacDonald, Kimberly C. Banks, Carol A. Lee, Barbara U. Schwerin, Margaret Juarez, Gwen C. Uman, Jeffrey N. Weitzel. (2008) Influence of genetic discrimination perceptions and knowledge on cancer genetics referral practice among clinicians. Genetics in Medicine 10:9, 691-698
CrossRef153
Ismail Jatoi, William F. Anderson. (2008) Management of Women Who Have a Genetic Predisposition for Breast Cancer. Surgical Clinics of North America 88:4, 845-861
CrossRef154
Roger A. Greenberg. (2008) Recognition of DNA double strand breaks by the BRCA1 tumor suppressor network. Chromosoma 117:4, 305-317
CrossRef155
Henry T. Lynch, Edibaldo Silva, Debrah Wirtzfeld, Pamela Hebbard, Jane Lynch, David G. Huntsman. (2008) Hereditary Diffuse Gastric Cancer: Prophylactic Surgical Oncology Implications. Surgical Clinics of North America 88:4, 759-778
CrossRef156
Anthony Howell. (2008) The endocrine prevention of breast cancer. Best Practice & Research Clinical Endocrinology & Metabolism 22:4, 615-623
CrossRef157
Janice S. Kwon, Charlotte C. Sun, Susan K. Peterson, Kristin G. White, Molly S. Daniels, Stephanie G. Boyd‐Rogers, Karen H. Lu. (2008) Cost‐effectiveness analysis of prevention strategies for gynecologic cancers in Lynch syndrome. Cancer 113:2, 326-335
CrossRef158
K.H. Baumann, U. Wagner. (2008) Präventionsstrategien beim Ovarialkarzinom. Der Gynäkologe 41:7, 513-522
CrossRef159
N. Biglia, L. Mariani, R. Ponzone, P. Sismondi. (2008) Oral contraceptives, salpingo-oophorectomy and hormone replacement therapy in BRCA1–2 mutation carriers. Maturitas 60:2, 71-77
CrossRef160
Ellen Warner. (2008) The Role of Magnetic Resonance Imaging in Screening Women at High Risk of Breast Cancer. Topics in Magnetic Resonance Imaging 19:3, 163-169
CrossRef161
Y. N. You, V. T. Lakhani, S. A. Wells. (2008) Reply. World Journal of Surgery 32:6, 1221-1222
CrossRef162
Antonis C. Antoniou, Amanda B. Spurdle, Olga M. Sinilnikova, Sue Healey, Karen A. Pooley, Rita K. Schmutzler, Beatrix Versmold, Christoph Engel, Alfons Meindl, Norbert Arnold, Wera Hofmann, Christian Sutter, Dieter Niederacher, Helmut Deissler, Trinidad Caldes, Kati Kämpjärvi, Heli Nevanlinna, Jacques Simard, Jonathan Beesley, Xiaoqing Chen, Susan L. Neuhausen, Timothy R. Rebbeck, Theresa Wagner, Henry T. Lynch, Claudine Isaacs, Jeffrey Weitzel, Patricia A. Ganz, Mary B. Daly, Gail Tomlinson, Olufunmilayo I. Olopade, Joanne L. Blum, Fergus J. Couch, Paolo Peterlongo, Siranoush Manoukian, Monica Barile, Paolo Radice, Csilla I. Szabo, Lutecia H. Mateus Pereira, Mark H. Greene, Gad Rennert, Flavio Lejbkowicz, Ofra Barnett-Griness, Irene L. Andrulis, Hilmi Ozcelik, Anne-Marie Gerdes, Maria A. Caligo, Yael Laitman, Bella Kaufman, Roni Milgrom, Eitan Friedman, Susan M. Domchek, Katherine L. Nathanson, Ana Osorio, Gemma Llort, Roger L. Milne, Javier Benítez, Ute Hamann, Frans B.L. Hogervorst, Peggy Manders, Marjolijn J.L. Ligtenberg, Ans M.W. van den Ouweland, Susan Peock, Margaret Cook, Radka Platte, D. Gareth Evans, Rosalind Eeles, Gabriella Pichert, Carol Chu, Diana Eccles, Rosemarie Davidson, Fiona Douglas, Andrew K. Godwin, Laure Barjhoux, Sylvie Mazoyer, Hagay Sobol, Violaine Bourdon, François Eisinger, Agnès Chompret, Corinne Capoulade, Brigitte Bressac-de Paillerets, Gilbert M. Lenoir, Marion Gauthier-Villars, Claude Houdayer, Dominique Stoppa-Lyonnet, Georgia Chenevix-Trench, Douglas F. Easton. (2008) Common Breast Cancer-Predisposition Alleles Are Associated with Breast Cancer Risk in BRCA1 and BRCA2 Mutation Carriers. The American Journal of Human Genetics 82:4, 937-948
CrossRef163
Nishan Chobanian, Charles S. Dietrich. (2008) Ovarian Cancer. Surgical Clinics of North America 88:2, 285-299
CrossRef164
Rachael Brandt, Zonera Ali, Allison Sabel, Terri McHugh, Paul Gilman. (2008) Cancer Genetics Evaluation: Barriers to and Improvements for Referral. Genetic Testing 12:1, 9-12
CrossRef165
Bernd Gerber, Max Dieterich, Heiner Müller, Toralf Reimer. (2008) Controversies in preservation of ovary function and fertility in patients with breast cancer. Breast Cancer Research and Treatment 108:1, 1-7
CrossRef166
Edibaldo Silva. (2008) Genetic counseling and clinical management of newly diagnosed breast cancer patients at genetic risk for BRCA germline mutations: perspective of a surgical oncologist. Familial Cancer 7:1, 91-95
CrossRef167
Kathleen Y Yang, Lee-may Chen. (2008) Gynecologic decisions for women at risk for Lynch syndrome. Expert Review of Obstetrics & Gynecology 3:2, 231-237
CrossRef168
Karen H. Lu. (2008) Hereditary gynecologic cancers: differential diagnosis, surveillance, management and surgical prophylaxis. Familial Cancer 7:1, 53-58
CrossRef169
Angela R. Bradbury, Comfort N. Ibe, James J. Dignam, Shelly A. Cummings, Marion Verp, Melody A. White, Grazia Artioli, Laura Dudlicek, Olufunmilayo I. Olopade. (2008) Uptake and timing of bilateral prophylactic salpingo-oophorectomy among BRCA1 and BRCA2 mutation carriers. Genetics in Medicine 10:3, 161-166
CrossRef170
L P Jones, M T Tilli, S Assefnia, K Torre, E D Halama, A Parrish, E M Rosen, P A Furth. (2008) Activation of estrogen signaling pathways collaborates with loss of Brca1 to promote development of ERα-negative and ERα-positive mammary preneoplasia and cancer. Oncogene 27:6, 794-802
CrossRef171
Edibaldo Silva, Zoran Gatalica, Carrie Snyder, Semir Vranic, Jane F. Lynch, Henry T. Lynch. (2008) Hereditary Breast Cancer: Part II. Management of Hereditary Breast Cancer: Implications of Molecular Genetics and Pathology. The Breast Journal 14:1, 14-24
CrossRef172
Lisa A Devlin, Patrick J Morrison. (2008) Inherited gynaecological cancer syndromes. The Obstetrician & Gynaecologist 10:1, 9-15
CrossRef173
Annette R. Patterson, Helen Davis, Kristin Shelby, Jerry McCoy, Linda D. Robinson, Smita K. Rao, Pia Banerji, Gail E. Tomlinson. (2008) Successful Strategies for Increasing African American Participation in Cancer Genetic Studies: Hopeful Signs for Equalizing the Benefits of Genetic Medicine. Community Genetics 11:4, 208-214
CrossRef174
Anthony P. Gulati, Susan M. Domchek. (2008) The clinical management of BRCA1 and BRCA2 mutation carriers. Current Oncology Reports 10:1, 47-53
CrossRef175
Michael Fatouros, Georgios Baltoyiannis, Dimitrios H. Roukos. (2008) The Predominant Role of Surgery in the Prevention and New Trends in the Surgical Treatment of Women With BRCA1/2 Mutations. Annals of Surgical Oncology 15:1, 21-33
CrossRef176
Henry T. Lynch, Edibaldo Silva, Carrie Snyder, Jane F. Lynch. (2008) Hereditary Breast Cancer: Part I. Diagnosing Hereditary Breast Cancer Syndromes. The Breast Journal 14:1, 3-13
CrossRef177
Antonis C. Antoniou, Olga M. Sinilnikova, Jacques Simard, Mélanie Léoné, Martine Dumont, Susan L. Neuhausen, Jeffery P. Struewing, Dominique Stoppa-Lyonnet, Laure Barjhoux, David J. Hughes, Isabelle Coupier, Muriel Belotti, Christine Lasset, Valérie Bonadona, Yves-Jean Bignon, Timothy R. Rebbeck, Theresa Wagner, Henry T. Lynch, Susan M. Domchek, Katherine L. Nathanson, Judy E. Garber, Jeffrey Weitzel, Steven A. Narod, Gail Tomlinson, Olufunmilayo I. Olopade, Andrew Godwin, Claudine Isaacs, Anna Jakubowska, Jan Lubinski, Jacek Gronwald, Bohdan Górski, Tomasz Byrski, Tomasz Huzarski, Susan Peock, Margaret Cook, Caroline Baynes, Alexandra Murray, Mark Rogers, Peter A. Daly, Huw Dorkins, Rita K. Schmutzler, Beatrix Versmold, Christoph Engel, Alfons Meindl, Norbert Arnold, Dieter Niederacher, Helmut Deissler, Amanda B. Spurdle, Xiaoqing Chen, Nicola Waddell, Nicole Cloonan, Tomas Kirchhoff, Kenneth Offit, Eitan Friedman, Bella Kaufmann, Yael Laitman, Gilli Galore, Gad Rennert, Flavio Lejbkowicz, Leon Raskin, Irene L. Andrulis, Eduard Ilyushik, Hilmi Ozcelik, Peter Devilee, Maaike P.G. Vreeswijk, Mark H. Greene, Sheila A. Prindiville, Ana Osorio, Javier Benítez, Michal Zikan, Csilla I. Szabo, Outi Kilpivaara, Heli Nevanlinna, Ute Hamann, Francine Durocher, Adalgeir Arason, Fergus J. Couch, Douglas F. Easton, Georgia Chenevix-Trench. (2007) RAD51 135G→C Modifies Breast Cancer Risk among BRCA2 Mutation Carriers: Results from a Combined Analysis of 19 Studies. The American Journal of Human Genetics 81:6, 1186-1200
CrossRef178
ER Woodward, HV Sleightholme, AM Considine, S Williamson, JM McHugo, DG Cruger. (2007) Annual surveillance by CA125 and transvaginal ultrasound for ovarian cancer in both high-risk and population risk women is ineffective. BJOG: An International Journal of Obstetrics & Gynaecology 114:12, 1500-1509
CrossRef179
James D. Fackenthal, Olufunmilayo I. Olopade. (2007) Breast cancer risk associated with BRCA1 and BRCA2 in diverse populations. Nature Reviews Cancer 7:12, 937-948
CrossRef180
Shawna C. Willey, Costanza Cocilovo. (2007) Screening and Follow-up of the Patient at High Risk for Breast Cancer. Obstetrics & Gynecology 110:6, 1404-1416
CrossRef181
James C. Pavelka, Andrew J. Li, Beth Y. Karlan. (2007) Hereditary Ovarian Cancer—Assessing Risk and Prevention Strategies. Obstetrics and Gynecology Clinics of North America 34:4, 651-665
CrossRef182
Rebecca Byler Dann, Joseph L. Kelley, Kristin K. Zorn. (2007) Strategies for Ovarian Cancer Prevention. Obstetrics and Gynecology Clinics of North America 34:4, 667-686
CrossRef183
Karin Leunen, Maria Drijkoningen, Patrick Neven, Maria-Rose Christiaens, Chantal Ongeval, Eric Legius, Frédéric Amant, Patrick Berteloot, Ignace Vergote. (2007) Prophylactic mastectomy in familial breast carcinoma. What do the pathologic findings learn us?. Breast Cancer Research and Treatment 107:1, 79-86
CrossRef184
Regina H. Kenen, Pamela J. Shapiro, Liisa Hantsoo, Susan Friedman, James C. Coyne. (2007) Women with BRCA1 or BRCA2 Mutations Renegotiating a Post-Prophylactic Mastectomy Identity: Self-Image and Self-Disclosure.. Journal of Genetic Counseling 16:6, 789-798
CrossRef185
Christine S. Walsh, Beth Y. Karlan. (2007) Contemporary progress in ovarian cancer screening. Current Oncology Reports 9:6, 485-493
CrossRef186
Angela R. Bradbury, Olufunmilayo I. Olopade. (2007) Genetic susceptibility to breast cancer. Reviews in Endocrine and Metabolic Disorders 8:3, 255-267
CrossRef187
Estelamari Rodriquez, Susan M. Domchek. (2007) The Prevention of Hereditary Breast Cancer. Seminars in Oncology 34:5, 401-405
CrossRef188
Dimitrios H Roukos, Evangelos Briasoulis. (2007) Individualized preventive and therapeutic management of hereditary breast ovarian cancer syndrome. Nature Clinical Practice Oncology 4:10, 578-590
CrossRef189
Bernardo Bonanni, Matteo Lazzeroni, Umberto Veronesi. (2007) Does tamoxifen prophylaxis for breast cancer provide long-term prevention?. Nature Clinical Practice Oncology 4:10, 568-569
CrossRef190
Siobhan M. Kehoe, Noah D. Kauff. (2007) Screening and Prevention of Hereditary Gynecologic Cancers. Seminars in Oncology 34:5, 406-410
CrossRef191
Rebecca Dent, Ellen Warner. (2007) Screening for Hereditary Breast Cancer. Seminars in Oncology 34:5, 392-400
CrossRef192
Dalliah Black, Michelle Specht, Janie M. Lee, Francisco Dominguez, Michele Gadd, Kevin Hughes, Elizabeth Rafferty, Barbara Smith. (2007) Detecting Occult Malignancy in Prophylactic Mastectomy: Preoperative MRI Versus Sentinel Lymph Node Biopsy. Annals of Surgical Oncology 14:9, 2477-2484
CrossRef193
Pal Moller, D. Gareth Evans, Marta M. Reis, Helen Gregory, Elaine Anderson, Lovise Maehle, Fiona Lalloo, Anthony Howell, Jaran Apold, Neal Clark, Anneke Lucassen, C. Michael Steel. (2007) Surveillance for familial breast cancer: Differences in outcome according toBRCA mutation status. International Journal of Cancer 121:5, 1017-1020
CrossRef194
Holly Etchegary, Colin Perrier. (2007) Information Processing in the Context of Genetic Risk: Implications for Genetic-Risk Communication. Journal of Genetic Counseling 16:4, 419-432
CrossRef195
Diana S. Rosman, Virginia Kaklamani, Boris Pasche. (2007) New Insights into Breast Cancer Genetics and Impact on Patient Management. Current Treatment Options in Oncology 8:1, 61-73
CrossRef196
Kristi D. Graves, Beth N. Peshkin, Chanita H. Halbert, Tiffani A. DeMarco, Claudine Isaacs, Marc D. Schwartz. (2007) Predictors and outcomes of contralateral prophylactic mastectomy among breast cancer survivors. Breast Cancer Research and Treatment 104:3, 321-329
CrossRef197
Anne I. Hagen, Kjell Arne Kvistad, Lovise Maehle, Marit Muri Holmen, Hildegunn Aase, Bodil Styr, Anita Vabø, Jaran Apold, Per Skaane, Pål Møller. (2007) Sensitivity of MRI versus conventional screening in the diagnosis of BRCA-associated breast cancer in a national prospective series. The Breast 16:4, 367-374
CrossRef198
William H Parker, Donna Shoupe, Michael S Broder, Zhimei Liu, Cindy Farquhar, Jonathan S Berek. (2007) Elective oophorectomy in the gynecological patient: when is it desirable?. Current Opinion in Obstetrics and Gynecology 19:4, 350-354
CrossRef199
Regina H. Kenen, Pamela J. Shapiro, Susan Friedman, James C. Coyne. (2007) Peer-support in coping with medical uncertainty: discussion of oophorectomy and hormone replacement therapy on a web-based message board. Psycho-Oncology 16:8, 763-771
CrossRef200
Mira Lessick. (2007) Genetic Testing for Breast and Ovarian Cancer: Ethical, Legal, and Psychosocial Considerations. Nursing for Women's Health 11:4, 390-401
CrossRef201
M.J. Bermejo-Pérez, S. Márquez-Calderón, A. Llanos-Méndez. (2007) Effectiveness of preventive interventions inBRCA1/2 gene mutation carriers: A systematic review. International Journal of Cancer 121:2, 225-231
CrossRef202
Robson, Mark, Offit, Kenneth, . (2007) Management of an Inherited Predisposition to Breast Cancer. New England Journal of Medicine 357:2, 154-162
Full Text203
Pål Møller, Anne Irene Hagen, Jaran Apold, Lovise Maehle, Neal Clark, Bent Fiane, Kjell Løvslett, Eivind Hovig, Anita Vabø. (2007) Genetic epidemiology of BRCA mutations – family history detects less than 50% of the mutation carriers. European Journal of Cancer 43:11, 1713-1717
CrossRef204
B.B.J. Hermsen, R.H.M. Verheijen, F.H. Menko, J.J.P. Gille, K. van Uffelen, M.A. Blankenstein, S. Meijer, P.J. van Diest, P. Kenemans, S. von Mensdorff-Pouilly. (2007) Humoral immune responses to MUC1 in women with a BRCA1 or BRCA2 mutation. European Journal of Cancer 43:10, 1556-1563
CrossRef205
Lee-may Chen, Kathleen Y. Yang, Sarah E. Little, Michael K. Cheung, Aaron B. Caughey. (2007) Gynecologic Cancer Prevention in Lynch Syndrome/Hereditary Nonpolyposis Colorectal Cancer Families. Obstetrics & Gynecology 110:1, 18-25
CrossRef206
Beth Y. Karlan, Andrew Berchuck, David Mutch. (2007) The Role of Genetic Testing for Cancer Susceptibility in Gynecologic Practice. Obstetrics & Gynecology 110:1, 155-167
CrossRef207
Janice L. Berliner, Angela Musial Fay. (2007) Risk Assessment and Genetic Counseling for Hereditary Breast and Ovarian Cancer: Recommendations of the National Society of Genetic Counselors. Journal of Genetic Counseling 16:3, 241-260
CrossRef208
Claire E. Wakefield, Bettina Meiser, Judi Homewood, Michelle Peate, Judy Kirk, Beverley Warner, Elizabeth Lobb, Clara Gaff, Kathy Tucker. (2007) Development and Pilot Testing of Two Decision Aids for Individuals Considering Genetic Testing for Cancer Risk. Journal of Genetic Counseling 16:3, 325-339
CrossRef209
Theresa A. Beery, Janet K. Williams. (2007) Risk Reduction and Health Promotion Behaviors Following Genetic Testing for Adult-Onset Disorders. Genetic Testing 11:2, 111-123
CrossRef210
Giovanni D. Aletti, Mary M. Gallenberg, William A. Cliby, Aminah Jatoi, Lynn C. Hartmann. (2007) Current Management Strategies for Ovarian Cancer. Mayo Clinic Proceedings 82:6, 751-770
CrossRef211
G. D. Aletti, M. M. Gallenberg, W. A. Cliby, A. Jatoi, L. C. Hartmann. (2007) Current Management Strategies for Ovarian Cancer. Mayo Clinic Proceedings 82:6, 751-770
CrossRef212
A. Staebler, J. Diebold. (2007) Molekularpathologie der epithelialen Ovarialneoplasien. Der Pathologe 28:3, 180-186
CrossRef213
B B J Hermsen, R I Olivier, R H M Verheijen, M van Beurden, J A de Hullu, L F Massuger, C W Burger, C T Brekelmans, M J Mourits, G H de Bock, K N Gaarenstroom, H H van Boven, T M Mooij, M A Rookus. (2007) No efficacy of annual gynaecological screening in BRCA1/2 mutation carriers; an observational follow-up study. British Journal of Cancer
CrossRef214
Francesco Sardanelli, Franca Podo. (2007) Breast MR imaging in women at high-risk of breast cancer. Is something changing in early breast cancer detection?. European Radiology 17:4, 873-887
CrossRef215
Shaheen Zakaria, Amy C. Degnim. (2007) Prophylactic Mastectomy. Surgical Clinics of North America 87:2, 317-331
CrossRef216
Gemma Llort, Mercè Peris, Ignacio Blanco. (2007) Cáncer de mama y ovario hereditario: prevención primaria y secundaria en mujeres portadoras de mutación en los genes BRCA1 y BRCA2. Medicina Clínica 128:12, 468-476
CrossRef217
Y. Nancy You, Vipul T. Lakhani, Samuel A. Wells. (2007) The Role of Prophylactic Surgery in Cancer Prevention. World Journal of Surgery 31:3, 450-464
CrossRef218
Susan M Domchek, Timothy R Rebbeck. (2007) Prophylactic oophorectomy in women at increased cancer risk. Current Opinion in Obstetrics and Gynecology 19:1, 27-30
CrossRef219
J Gronwald, T Byrski, T Huzarski, C Cybulski, M Stawicka, M Szwiec, T Dębniak, A Tulman, P Sun, O Oszurek, J Lubinski, SA Narod. (2007) A survey of preventive measures among BRCA1 mutation carriers from Poland. Clinical Genetics 71:2, 153-157
CrossRef220
O. E. Fedorova, L. N. Lyubchenko, Yu. G. Payanidi, T. P. Kazubskaya, F. A. Amosenko, R. F. Garkavtseva, A. S. Zasedatelev, T. V. Nasedkina. (2007) Biochip analysis of BRCA1/2 and CHEK2 common mutations in ovarian cancer and primary multiple tumors involving the ovaries (Russian population). Molecular Biology 41:1, 32-36
CrossRef221
Dianne D. Chapman. (2007) Cancer Genetics. Seminars in Oncology Nursing 23:1, 2-9
CrossRef222
Sudhir Srivastava, Paul D Wagner. (2007) Risk-based and diagnostics-linked personalized medicine for cancer. Personalized Medicine 4:1, 33-43
CrossRef223
Mario E. Beiner, Amy Finch, Barry Rosen, Jan Lubinski, Pal Moller, Parviz Ghadirian, Henry T. Lynch, Eitan Friedman, Ping Sun, Steven A. Narod. (2007) The risk of endometrial cancer in women with BRCA1 and BRCA2 mutations. A prospective study. Gynecologic Oncology 104:1, 7-10
CrossRef224
Karen H. Lu, Noah D. Kauff. (2007) Does a BRCA mutation plus tamoxifen equal hysterectomy?. Gynecologic Oncology 104:1, 3-4
CrossRef225
Fabienne Patricia Liebens, Birgit Carly, Ann Pastijn, Serge Rozenberg. (2007) Management of BRCA1/2 associated breast cancer: A systematic qualitative review of the state of knowledge in 2006. European Journal of Cancer 43:2, 238-257
CrossRef226
Louise J. Bordeleau, Joan E. Lipa, Peter C. Neligan. (2007) Management of the BRCA Mutation Carrier or High-Risk Patient. Clinics in Plastic Surgery 34:1, 15-27
CrossRef227
Jennifer Scalia Wilbur, Adam A. Rojan, Robert D. Legare. 2007. The Genetics of Breast and Gynecologic Cancers. , 43-71.
CrossRef228
2007. B. , 26-38.
CrossRef229
Vardit Kram, Tamar Peretz, Michal Sagi. (2006) Acceptance of Preventive Surgeries by Israeli Women Who had Undergone BRCA Testing. Familial Cancer 5:4, 327-335
CrossRef230
Rita K. Schmutzler, Kerstin Rhiem, Petra Breuer, Eva Wardelmann, Martin Lehnert, Silke Coburger, Barbara Wappenschmidt. (2006) Outcome of a structured surveillance programme in women with a familial predisposition for breast cancer. European Journal of Cancer Prevention 15:6, 483-489
CrossRef231
W.H. Gotlieb, M. Barchana, G. Ben-Baruch, E. Friedman. (2006) Malignancies following bilateral salpingo-oophorectomy (BSO). European Journal of Surgical Oncology (EJSO) 32:10, 1231-1234
CrossRef232
June A. Peters, Lindsey Hoskins, Sheila Prindiville, Regina Kenen, Mark H. Greene. (2006) Evolution of the Colored Eco-Genetic Relationship Map (CEGRM) for Assessing Social Functioning in Women in Hereditary Breast-Ovarian (HBOC) Families. Journal of Genetic Counseling 15:6, 477-489
CrossRef233
Kristin Bosse, Kerstin Rhiem, Barbara Wappenschmidt, Martin Hellmich, Martin Madeja, Monika Ortmann, Peter Mallmann, Rita Schmutzler. (2006) Screening for ovarian cancer by transvaginal ultrasound and serum CA125 measurement in women with a familial predisposition: A prospective cohort study. Gynecologic Oncology 103:3, 1077-1082
CrossRef234
K CHAN, T SELMAN. (2006) Testing for ovarian cancer. Best Practice & Research Clinical Obstetrics & Gynaecology 20:6, 977-983
CrossRef235
Suzanne M. O'Neill, June A. Peters, Victor G. Vogel, Eleanor Feingold, Wendy S. Rubinstein. (2006) Referral to cancer genetic counseling: Are there stages of readiness?. American Journal of Medical Genetics Part C: Seminars in Medical Genetics 142C:4, 221-231
CrossRef236
J. Chang-Claude, C. Fischer, R. Schmutzler. (2006) Genetische Epidemiologie am Beispiel Brustkrebs. Der Onkologe 12:11, 1126-1135
CrossRef237
Nicoletta Colombo, Toon Van Gorp, Gabriella Parma, Frederic Amant, Gemma Gatta, Cristiana Sessa, Ignace Vergote. (2006) Ovarian cancer. Critical Reviews in Oncology/Hematology 60:2, 159-179
CrossRef238
Carolyn Y. Fang, Mary B. Daly, Suzanne M. Miller, Tana Zerr, John Malick, Paul Engstrom. (2006) Coping with ovarian cancer risk: The moderating effects of perceived control on coping and adjustment. British Journal of Health Psychology 11:4, 561-580
CrossRef239
Kent F. Hoskins, Alice Zwaagstra, Michael Ranz. (2006) Validation of a tool for identifying women at high risk for hereditary breast cancer in population-based screening. Cancer 107:8, 1769-1776
CrossRef240
Izabella Rzepka-Górska, Bogusław Tarnowski, Anita Chudecka-Głaz, Bohdan Górski, Dorota Zielińska, Aleksandra Tołoczko-Grabarek. (2006) Premature Menopause in Patients with BRCA1 Gene Mutation. Breast Cancer Research and Treatment 100:1, 59-63
CrossRef241
Maria L. Carcangiu, Bernard Peissel, Barbara Pasini, Gianbattista Spatti, Paolo Radice, Siranoush Manoukian. (2006) Incidental Carcinomas in Prophylactic Specimens in BRCA1 and BRCA2 Germ-line Mutation Carriers, With Emphasis on Fallopian Tube Lesions. The American Journal of Surgical Pathology 30:10, 1222-1230
CrossRef242
A. Sharma, U. Menon. (2006) Screening for gynaecological cancers. European Journal of Surgical Oncology (EJSO) 32:8, 818-824
CrossRef243
José G. Guillem, William C. Wood, Jeffrey F. Moley, Andrew Berchuck, Beth Y. Karlan, David G. Mutch, Robert F. Gagel, Jeffrey Weitzel, Monica Morrow, Barbara L. Weber, Francis Giardiello, Miguel A. Rodriguez-Bigas, James Church, Stephen Gruber, Kenneth Offit. (2006) ASCO/SSO Review of Current Role of Risk-Reducing Surgery in Common Hereditary Cancer Syndromes. Annals of Surgical Oncology 13:10, 1296-1321
CrossRef244
A C Antoniou, D F Easton. (2006) Models of genetic susceptibility to breast cancer. Oncogene 25:43, 5898-5905
CrossRef245
S M Domchek, B L Weber. (2006) Clinical management of BRCA1 and BRCA2 mutation carriers. Oncogene 25:43, 5825-5831
CrossRef246
Brenda B.J. Hermsen, Paul J. van Diest, Johannes Berkhof, Fred H. Menko, Johan J.P. Gille, Jurgen M.J. Piek, Sybren Meijer, Henri A.H. Winters, Peter Kenemans, Silvia von Mensdorff-Pouilly, René H.M. Verheijen. (2006) Low prevalence of (pre) malignant lesions in the breast and high prevalence in the ovary and Fallopian tube in women at hereditary high risk of breast and ovarian cancer. International Journal of Cancer 119:6, 1412-1418
CrossRef247
Kathleen M. Schmeler, Charlotte C. Sun, Diane C. Bodurka, Kristin G. White, Pamela T. Soliman, Anne R. Uyei, Julie L. Erlichman, Banu K. Arun, Molly S. Daniels, Susan A. Rimes, Susan K. Peterson, Brian M. Slomovitz, Michael R. Milam, David M. Gershenson, Karen H. Lu. (2006) Prophylactic Bilateral Salpingo-Oophorectomy Compared With Surveillance in Women With BRCA Mutations. Obstetrics & Gynecology 108:3, Part 1, 515-520
CrossRef248
Nicole Urban, Charles Drescher. (2006) Current and future developments in screening for ovarian cancer. Women's Health 2:5, 733-742
CrossRef249
BOBBIE S. GOSTOUT, MOLLY A. BREWER. (2006) Guidelines for Referral of the Patient With an Adnexal Mass. Clinical Obstetrics and Gynecology 49:3, 448-458
CrossRef250
K-A Phillips, MA Jenkins, GJ Lindeman, SA McLachlan, JM McKinley, PC Weideman, JL Hopper, ML Friedlander, . (2006) Risk-reducing surgery, screening and chemoprevention practices of BRCA1 and BRCA2 mutation carriers: a prospective cohort study. Clinical Genetics 70:3, 198-206
CrossRef251
Kelly E. Happe. (2006) Heredity, gender and the discourse of ovarian cancer. New Genetics and Society 25:2, 171-196
CrossRef252
Inga Peter, Kevin Chin. (2006) Overview of genetic testing in cancer. Personalized Medicine 3:3, 325-333
CrossRef253
Ram Eitan, Robert Soslow, Oscar Lin, Noah D. Kauff, Lisa Liu, Richard R. Barakat, Dennis S. Chi. (2006) The significance of cytological mesothelial atypia diagnosed from peritoneal washings performed during risk-reducing salpingo-oophorectomy. Gynecologic Oncology 102:2, 315-318
CrossRef254
W. F. Anderson, R. Matsuno. (2006) Breast Cancer Heterogeneity: A Mixture of At Least Two Main Types?. JNCI Journal of the National Cancer Institute 98:14, 948-951
CrossRef255
M.-L. Asselin-Labat, M. Shackleton, J. Stingl, F. Vaillant, N. C. Forrest, C. J. Eaves, J. E. Visvader, G. J. Lindeman. (2006) Steroid Hormone Receptor Status of Mouse Mammary Stem Cells. JNCI Journal of the National Cancer Institute 98:14, 1011-1014
CrossRef256
Priscilla F. McAuliffe, William G. Cance. (2006) Preemptive surgery. Surgery 140:1, 1-5
CrossRef257
D. Rein, N. Arnold, D. Niederacher. (2006) Ovarialkarzinom. Der Gynäkologe 39:6, 420-427
CrossRef258
Julie D. Lamb, Rochelle L. Garcia, Barbara A. Goff, Pamela J. Paley, Elizabeth M. Swisher. (2006) Predictors of occult neoplasia in women undergoing risk-reducing salpingo-oophorectomy. American Journal of Obstetrics and Gynecology 194:6, 1702-1709
CrossRef259
Snehal Bhoola, William J. Hoskins. (2006) Diagnosis and Management of Epithelial Ovarian Cancer. Obstetrics & Gynecology 107:6, 1399-1410
CrossRef260
Jacek Gronwald, Nadine Tung, William D. Foulkes, Kenneth Offit, Ruth Gershoni, Mary Daly, Charmaine Kim-Sing, Hakan Olsson, Peter Ainsworth, Andrea Eisen, Howard Saal, Eitan Friedman, Olufunmilayo Olopade, Michael Osborne, Jeffrey Weitzel, Henry Lynch, Parviz Ghadirian, Jan Lubinski, Ping Sun, Steven A. Narod, . (2006) Tamoxifen and contralateral breast cancer inBRCA1 andBRCA2 carriers: An update. International Journal of Cancer 118:9, 2281-2284
CrossRef261
E Winchester, Shirley V Hodgson. (2006) Psychosocial and ethical issues relating to genetic testing for BRCA1 and BRCA2 breast cancer susceptibility genes. Women's Health 2:3, 357-373
CrossRef262
M Bramley, R B Clarke, A Howell, D G R Evans, T Armer, A D Baildam, E Anderson. (2006) Effects of oestrogens and anti-oestrogens on normal breast tissue from women bearing BRCA1 and BRCA2 mutations. British Journal of Cancer 94:7, 1021-1028
CrossRef263
Antonis C Antoniou, Douglas F Easton. (2006) Risk prediction models for familial breast cancer. Future Oncology 2:2, 257-274
CrossRef264
A ROSENTHAL, I JACOBS. (2006) Familial ovarian cancer screening. Best Practice & Research Clinical Obstetrics & Gynaecology 20:2, 321-338
CrossRef265
L HANNA, M ADAMS. (2006) Prevention of ovarian cancer. Best Practice & Research Clinical Obstetrics & Gynaecology 20:2, 339-362
CrossRef266
A L Oei, L F Massuger, J Bulten, M J Ligtenberg, N Hoogerbrugge, J A de Hullu. (2006) Surveillance of women at high risk for hereditary ovarian cancer is inefficient. British Journal of Cancer 94:6, 814-819
CrossRef267
Nina Hallowell. (2006) Varieties of suffering: Living with the risk of ovarian cancer. Health, Risk & Society 8:1, 9-26
CrossRef268
Elissa M. Ozanne, Jennifer R. Klemp, Laura J. Esserman. (2006) Breast Cancer Risk Assessment and Prevention: A Framework for Shared Decision-Making Consultations. The Breast Journal 12:2, 103-113
CrossRef269
Orland Díez, Sara Gutiérrez-Enríquez, Teresa Ramón Cajal. (2006) Genes de susceptibilidad al cáncer de mama. Medicina Clínica 126:8, 304-310
CrossRef270
Susan M Domchek, Tara M Friebel, Susan L Neuhausen, Theresa Wagner, Gareth Evans, Claudine Isaacs, Judy E Garber, Mary B Daly, Rosalind Eeles, Ellen Matloff, Gail E Tomlinson, Laura Van't Veer, Henry T Lynch, Olufunmilayo I Olopade, Barbara L Weber, Timothy R Rebbeck. (2006) Mortality after bilateral salpingo-oophorectomy in BRCA1 and BRCA2 mutation carriers: a prospective cohort study. The Lancet Oncology 7:3, 223-229
CrossRef271
Cecile TM Brekelmans, Caroline Seynaeve. (2006) Can bilateral prophylactic salpingo-oophorectomy reduce cancer mortality in carriers of a BRCA1 or BRCA2 mutation?. The Lancet Oncology 7:3, 191-193
CrossRef272
G.C. RIECK, K. LIM, M.T. ROGERS, E. FRANCE, J.R. GRAY, N. AMSO, A.S. EVANS, R.H. HOWELLS, A.N. FIANDER. (2006) Screening for familial ovarian cancer-management and outcome of women with moderate to high risk of developing ovarian cancer. International Journal of Gynecological Cancer 16:S1, 86-91
CrossRef273
K.N. GAARENSTROOM, B. van der HIEL, R.A.E.M. TOLLENAAR, G.R. VINK, F.W. JANSEN, C.J. van ASPEREN, G.G. KENTER. (2006) Efficacy of screening women at high risk of hereditary ovarian cancer: results of an 11-year cohort study. International Journal of Gynecological Cancer 16:S1, 54-59
CrossRef274
K.S. JAABACK, L. LUDEMAN, N.L. CLAYTON, L. HIRSCHOWITZ. (2006) Primary peritoneal carcinoma in a UK cancer center: comparison with advanced ovarian carcinoma over a 5-year period. International Journal of Gynecological Cancer 16:S1, 123-128
CrossRef275
H M Verkooijen, P O Chappuis, E Rapiti, G Vlastos, G Fioretta, S Sarp, A P Sappino, H Schubert, C Bouchardy. (2006) Impact of familial risk factors on management and survival of early-onset breast cancer: a population-based study. British Journal of Cancer 94:2, 231-238
CrossRef276
Schmeler, Kathleen M., Lynch, Henry T., Chen, Lee-may, Munsell, Mark F., Soliman, Pamela T., Clark, Mary Beth, Daniels, Molly S., White, Kristin G., Boyd-Rogers, Stephanie G., Conrad, Peggy G., Yang, Kathleen Y., Rubin, Mary M., Sun, Charlotte C., Slomovitz, Brian M., Gershenson, David M., Lu, Karen H., . (2006) Prophylactic Surgery to Reduce the Risk of Gynecologic Cancers in the Lynch Syndrome. New England Journal of Medicine 354:3, 261-269
Full Text277
E LYNCH, R EELES. (2006) Management of a woman with a family history of breast cancer. Women's Health Medicine 3:1, 28-30
CrossRef278
K. LEUNEN, E. LEGIUS, P. MOERMAN, F. AMANT, P. NEVEN, I. VERGOTE. (2006) Prophylactic salpingo-oophorectomy in 51 women with familial breast-ovarian cancer: importance of fallopian tube dysplasia. International Journal of Gynecological Cancer 16:1, 183-188
CrossRef279
Michael P. Lux, Peter A. Fasching, Matthias W. Beckmann. (2006) Hereditary breast and ovarian cancer: review and future perspectives. Journal of Molecular Medicine 84:1, 16-28
CrossRef280
Amy Finch, Patricia Shaw, Barry Rosen, Joan Murphy, Steven A. Narod, Terence J. Colgan. (2006) Clinical and pathologic findings of prophylactic salpingo-oophorectomies in 159 BRCA1 and BRCA2 carriers. Gynecologic Oncology 100:1, 58-64
CrossRef281
Dirk Olaf Bauerschlag, Christian Schem, Christoph Mundhenke, Ivo Meinhold-Heerlein, Walter Jonat, Nicolai Maass. (2006) Familial Breast Cancer, Prevention, Risk Factors and Genetics – Highlights from the San Antonio Breast Cancer Symposium (SABCS) Poster Presentations. Breast Care 1:2, 103-106
CrossRef282
Joanne Kotsopoulos, Jan Lubinski, Susan L. Neuhausen, Henry T. Lynch, Barry Rosen, Peter Ainsworth, Pal Moller, Parviz Ghadirian, Claudine Isaacs, Beth Karlan, Ping Sun, Steven A. Narod. (2006) Hormone replacement therapy and the risk of ovarian cancer in BRCA1 and BRCA2 mutation carriers. Gynecologic Oncology 100:1, 83-88
CrossRef283
André Nkondjock, Parviz Ghadirian, Joanne Kotsopoulos, Jan Lubinski, Henry Lynch, Charmaine Kim-Sing, Douglas Horsman, Barry Rosen, Claudine Isaacs, Barbara Weber, William Foulkes, Peter Ainsworth, Nadine Tung, Andrea Eisen, Eitan Friedman, Charis Eng, Ping Sun, Steven A. Narod. (2006) Coffee consumption and breast cancer risk amongBRCA1 andBRCA2 mutation carriers. International Journal of Cancer 118:1, 103-107
CrossRef284
C. Bethan Powell. (2006) Occult ovarian cancer at the time of risk-reducing salpingo-oophorectomy. Gynecologic Oncology 100:1, 1-2
CrossRef285
Bettina Kuschel, Evelyn Hauenstein, Marion Kiechle, Alfons Meindl. (2006) Hereditary Breast and Ovarian Cancer – Current Clinical Guidelines in Germany. Breast Care 1:1, 8-14
CrossRef286
Regina Kroiss, Diana Bikas, Verena Winkler, Daniela Muhr, Christine Fürhauser, Maria Tea, Elisabeth Fleischmann, Austrian Hereditary, Ernst Kubista, Teresa Wagner. (2006) Hereditary Breast and Ovarian Cancer: Structures of Care in Austria. Breast Care 1:1, 17-21
CrossRef287
Karen Lisa Smith, Mark E. Robson. (2006) Update on hereditary breast cancer. Current Oncology Reports 8:1, 14-21
CrossRef288
Susan M Domchek, Katrina Armstron, Barbara L Weber. (2006) Clinical management of BRCA1 and BRCA2 mutation carriers. Nature Clinical Practice Oncology 3:1, 2-3
CrossRef289
Marzia Palma, Elisabetta Ristori, Enrico Ricevuto, Giuseppe Giannini, Alberto Gulino. (2006) BRCA1 and BRCA2: The genetic testing and the current management options for mutation carriers. Critical Reviews in Oncology/Hematology 57:1, 1-23
CrossRef290
Yanfen Hu, Sagar Ghosh, Asma Amleh, Wei Yue, Yunzhe Lu, Adam Katz, Rong Li. (2005) Modulation of aromatase expression by BRCA1: a possible link to tissue-specific tumor suppression. Oncogene 24:56, 8343-8348
CrossRef291
M. P. Lux, M. R. Bani, P. A. Fasching, M. W. Beckmann. (2005) Prophylaktische Chirurgie des Mamma- und Ovarialkarzinoms. Der Chirurg 76:12, 1145-1154
CrossRef292
Jessica A. Ray, Lois J. Loescher, Molly Brewer. (2005) Risk-Reduction Surgery Decisions in High-Risk Women Seen for Genetic Counseling. Journal of Genetic Counseling 14:6, 473-484
CrossRef293
Karen L. Brown, Robin Hutchison, Randi E. Zinberg, Margaret M. McGovern. (2005) Referral and Experience with Genetic Testing Among Women with Early Onset Breast Cancer. Genetic Testing 9:4, 301-305
CrossRef294
D.G.R. Evans, F. Lalloo, P. Hopwood, A. Maurice, A. Baildam, A. Brain, L. Barr, A. Howell. (2005) Surgical decisions made by 158 women with hereditary breast cancer aged <50 years. European Journal of Surgical Oncology (EJSO) 31:10, 1112-1118
CrossRef295
Amanda Muir, Bettina Meiser, Monica Tucker, Lesley Andrews, Kathy Tucker, Michael Friedlander. (2005) The Feasibility of Women at High Risk for Breast Cancer Participating in Chemoprevention Trials. Journal of Psychosocial Oncology 22:4, 31-45
CrossRef296
Baldeep Wirk. (2005) The Role of Ovarian Ablation in the Management of Breast Cancer. The Breast Journal 11:6, 416-424
CrossRef297
Francisco J. Dominguez, Julie L. Jones, Katherina Zabicki, Barbara L. Smith, Michele A. Gadd, Michele Specht, Daniel B. Kopans, Richard H. Moore, James S. Michaelson, Kevin S. Hughes. (2005) Prevalence of hereditary breast/ovarian carcinoma risk in patients with a personal history of breast or ovarian carcinoma in a mammography population. Cancer 104:9, 1849-1853
CrossRef298
Ram Kerner, Edmond Sabo, Ruth Gershoni-Baruch, Dan Beck, Ofer Ben-Izhak. (2005) Expression of cell cycle regulatory proteins in ovaries prophylactically removed from Jewish Ashkenazi BRCA1 and BRCA2 mutation carriers: Correlation with histopathology. Gynecologic Oncology 99:2, 367-375
CrossRef299
Murat Sonmezer, Mousa Issa Shamonki, Kutluk Oktay. (2005) Ovarian tissue cryopreservation: benefits and risks. Cell and Tissue Research 322:1, 125-132
CrossRef300
Mehadad Noruzinia, Isabelle Coupier, Pascal Pujol. (2005) IsBRCA1/BRCA2-related breast carcinogenesis estrogen dependent?. Cancer 104:8, 1567-1574
CrossRef301
DG Cruger, TA Kruse, AM Gerdes. (2005) ‘Indirect’ BRCA1/2 testing. A useful approach in hereditary breast and ovarian cancer families without a living affected relative. Clinical Genetics 68:3, 228-233
CrossRef302
Lisa Madlensky, John R. McLaughlin, June C. Carroll, Vivek Goel, John W. Frank. (2005) Risks and benefits of population-based genetic testing for Mendelian subsets of common diseases were examined using the example of colorectal cancer risk. Journal of Clinical Epidemiology 58:9, 934-941
CrossRef303
Allison W. Kurian, Anne-Renee Hartman, Meredith A. Mills, James M. Ford, Bruce L. Daniel, Sylvia K. Plevritis. (2005) Opinions of women with high inherited breast cancer risk about prophylactic mastectomy: an initial evaluation from a screening trial including magnetic resonance imaging and ductal lavage. Health Expectations 8:3, 221-233
CrossRef304
M. Stumacher, S. M. Domchek. (2005) Update on chemoprevention in BRCA1 and BRCA2 mutation carriers. Breast Cancer Online 8:09,
CrossRef305
H. Karen Lu, Russell R. Broaddus. (2005) Gynecologic Cancers in Lynch Syndrome/HNPCC. Familial Cancer 4:3, 249-254
CrossRef306
T C van Sprundel, M K Schmidt, M A Rookus, R Brohet, C J van Asperen, E J Th Rutgers, L J van‘t Veer, R A E M Tollenaar. (2005) Risk reduction of contralateral breast cancer and survival after contralateral prophylactic mastectomy in BRCA1 or BRCA2 mutation carriers. British Journal of Cancer 93:3, 287-292
CrossRef307
(2005) Society of Gynecologic Oncologists Clinical Practice Committee Statement on Prophylactic Salpingo-oophorectomy. Gynecologic Oncology 98:2, 179-181
CrossRef308
Jaime Prat, Adriana Ribé, Alberto Gallardo. (2005) Hereditary ovarian cancer. Human Pathology 36:8, 861-870
CrossRef309
Noah D. Kauff, Karen E. Hurley, Martee L. Hensley, Mark E. Robson, Gali Lev, Deborah Goldfrank, Mercedes Castiel, Carol L. Brown, Jamie S. Ostroff, Lucy E. Hann, Kenneth Offit, Richard R. Barakat. (2005) Ovarian carcinoma screening in women at intermediate risk. Cancer 104:2, 314-320
CrossRef310
Veronica Collins, Bettina Meiser, Clara Gaff, D. James B. St. John, Jane Halliday. (2005) Screening and preventive behaviors one year after predictive genetic testing for hereditary nonpolyposis colorectal carcinoma. Cancer 104:2, 273-281
CrossRef311
Steven A Narod. (2005) Clinical implications of the breast cancer susceptibility genes BRCA1 and BRCA2. Women's Health 1:1, 27-34
CrossRef312
M. Kriege, C. T. M. Brekelmans, J. G. M. Klijn. (2005) MRI Screening for Breast Cancer in Women with a Familial or Genetic Predisposition. Imaging Decisions MRI 9:2, 11-18
CrossRef313
Kelly-Anne Phillips, Phyllis N. Butow, Ailsa E. Stewart, Jiun-Horng Chang, Prue C. Weideman, Melanie A. Price, Sue Anne McLachlan, kConFab Investigators, Geoffrey J. Lindeman, Michael J. McKay, Michael L. Friedlander, John L. Hopper. (2005) Predictors of participation in clinical and psychosocial follow-up of the kConFab breast cancer family cohort. Familial Cancer 4:2, 105-113
CrossRef314
Kelly A. Metcalfe, Carrie Snyder, Jennifer Seidel, Danielle Hanna, Henry T. Lynch, Steven Narod. (2005) The use of preventive measures among healthy women who carry a BRCA1 or BRCA2 mutation. Familial Cancer 4:2, 97-103
CrossRef315
Laundette P Jones, Minglin Li, Ewa D Halama, Yongxian Ma, Ronald Lubet, Clinton J Grubbs, Chu-Xia Deng, Eliot M Rosen, Priscilla A Furth. (2005) Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer. Oncogene 24:22, 3554-3562
CrossRef316
(2005) Guidelines for the management of symptomatic breast disease. European Journal of Surgical Oncology (EJSO) 31, 1-21
CrossRef317
Murray Joseph Casey, Carrie Synder, Chhanda Bewtra, Steven A. Narod, Patrice Watson, Henry T. Lynch. (2005) Intra-abdominal carcinomatosis after prophylactic oophorectomy in women of hereditary breast ovarian cancer syndrome kindreds associated with BRCA1 and BRCA2 mutations. Gynecologic Oncology 97:2, 457-467
CrossRef318
Paul A.M. Meeuwissen, Caroline Seynaeve, Cecile T.M. Brekelmans, Hanne J. Meijers-Heijboer, Jan G.M. Klijn, Curt W. Burger. (2005) Outcome of surveillance and prophylactic salpingo-oophorectomy in asymptomatic women at high risk for ovarian cancer. Gynecologic Oncology 97:2, 476-482
CrossRef319
K. Tiller, B. Meiser, L. Gould, K. Tucker, T. Dudding, J. Franklin, M. Friedlander, L. Andrews. (2005) Knowledge of risk management strategies, and information and risk management preferences of women at increased risk for ovarian cancer. Psycho-Oncology 14:4, 249-261
CrossRef320
Adam H. Buchanan, Celette Sugg Skinner, Susan M. Rawl, Barry K. Moser, Victoria L. Champion, Linda L. Scott, Tara S. Strigo, Lori Bastian. (2005) Patients’ interest in discussing cancer risk and risk management with primary care physicians. Patient Education and Counseling 57:1, 77-87
CrossRef321
Nikki Peters, Susan M. Domchek, Abigail Rose, Rachael Polis, Jill Stopfer, Katrina Armstrong. (2005) Knowledge, Attitudes, and Utilization of BRCA1/2 Testing among Women with Early-Onset Breast Cancer. Genetic Testing 9:1, 48-53
CrossRef322
Lisa Madlensky, Shirley W. Flatt, Wayne A. Bardwell, Cheryl L. Rock, John P. Pierce, . (2005) Is family history related to preventive health behaviors and medical management in breast cancer patients?. Breast Cancer Research and Treatment 90:1, 47-54
CrossRef323
Roelien I. Olivier, Lottie A.C. Lubsen-Brandsma, Hester van Boven, Marc van Beurden. (2005) Additional salpingectomy after previous prophylactic oophorectomy in high-risk women: sense or nonsense?. Gynecologic Oncology 96:2, 439-443
CrossRef324
Maren T. Scheuner. 2005. Approach to common chronic disorders of adulthood. .
CrossRef325
Abigail L. Rose, Nikki Peters, Judy A. Shea, Katrina Armstrong. (2005) Attitudes and Misconceptions about Predictive Genetic Testing for Cancer Risk. Community Genetics 8:3, 145-151
CrossRef326
Kelly A. Metcalfe, Henry T. Lynch, Parviz Ghadirian, Nadine Tung, Ivo A. Olivotto, William D. Foulkes, Ellen Warner, Olufunmilayo Olopade, Andrea Eisen, Barbara Weber, Jane McLennan, Ping Sun, Steven A. Narod. (2005) The risk of ovarian cancer after breast cancer in BRCA1 and BRCA2 carriers. Gynecologic Oncology 96:1, 222-226
CrossRef327
S Eliza Griffiths, Tito Lopes, Richard J Edmondson. (2005) The role of prophylactic salpingo-oophorectomy in women who carry mutations of the BRCA genes. The Obstetrician & Gynaecologist 7:1, 23-27
CrossRef328
Marc D. Schwartz, Beth N. Peshkin, Kenneth P. Tercyak, Kathryn L. Taylor, Heiddis Valdimarsdottir. (2005) Decision Making and Decision Support for Hereditary Breast-Ovarian Cancer Susceptibility.. Health Psychology 24:4, Suppl, S78-S84
CrossRef329
Kathleen R. Blazer, Deborah J. MacDonald, Charite Ricker, Sharon Sand, Gwen C. Uman, Jeffrey N. Weitzel. (2005) Outcomes from intensive training in genetic cancer risk counseling for clinicians. Genetics in Medicine 7:1, 40-47
CrossRef330
Cannistra, Stephen A., . (2004) Cancer of the Ovary. New England Journal of Medicine 351:24, 2519-2529
Full Text331
Lori d’Agincourt-Canning. (2004) Genetic testing for hereditary cancer: Challenges to ethical care in rural and remote communities. HEC Forum 16:4, 222-233
CrossRef332
Niki J. Agnantis, Evangelos Paraskevaidis, Dimitrios Roukos. (2004) Preventing Breast, Ovarian Cancer in BRCA Carriers: Rational of Prophylactic Surgery and Promises of Surveillance. Annals of Surgical Oncology 11:12, 1030-1034
CrossRef333
M Watson, C Foster, R Eeles, D Eccles, S Ashley, R Davidson, J Mackay, P J Morrison, P Hopwood, D G R Evans. (2004) Psychosocial impact of breast/ovarian (BRCA1/2) cancer-predictive genetic testing in a UK multi-centre clinical cohort. British Journal of Cancer 91:10, 1787-1794
CrossRef334
Ronit Calderon-Margalit, Ora Paltiel. (2004) Prevention of breast cancer in women who carryBRCA1 orBRCA2 mutations: A critical review of the literature. International Journal of Cancer 112:3, 357-364
CrossRef335
Sean C. Dowdy, Michael Stefanek, Lynn C. Hartmann. (2004) Surgical risk reduction: Prophylactic salpingo-oophorectomy and prophylactic mastectomy. American Journal of Obstetrics and Gynecology 191:4, 1113-1123
CrossRef336
T. E. Alpert, B. G. Haffty. (2004) Safety of breast conservation therapy in BRCA1 and BRCA2 cancers. Breast Cancer Online 7:09,
CrossRef337
Lesley Andrews, Bettina Meiser, Carmel Apicella, Katherine Tucker. (2004) Psychological Impact of Genetic Testing for Breast Cancer Susceptibility in Women of Ashkenazi Jewish Background: A Prospective Study. Genetic Testing 8:3, 240-247
CrossRef338
Steven A. Narod, William D. Foulkes. (2004) BRCA1 and BRCA2: 1994 and beyond. Nature Reviews Cancer 4:9, 665-676
CrossRef339
Henry T. Lynch, Wendy S. Rubinstein, Gershon Y. Locker. (2004) Cancer in Jews: introduction and overview. Familial Cancer 3:3-4, 177-192
CrossRef340
Alexander Olawaiye, Lori Caesar, Debra Walsh, Mollie Lyman, John Yeh, Kerry Rodabaugh, David Marchetti, Shashikant Lele, Kunle Odunsi. (2004) Analysis of the time interval between diagnoses in women with double primary breast and ovarian or primary peritoneal cancers. Gynecologic Oncology 94:3, 796-802
CrossRef341
S. Wacholder. (2004) Bias in Intervention Studies That Enroll Patients From High-Risk Clinics. JNCI Journal of the National Cancer Institute 96:16, 1204-1207
CrossRef342
Henry T. Lynch, Trudy G. Shaw, Jane F. Lynch. (2004) Inherited predisposition to cancer: A historical overview. American Journal of Medical Genetics 129C:1, 5-22
CrossRef343
Shirley V. Hodgson, Patrick J. Morrison, Melita Irving. (2004) Breast cancer genetics: Unsolved questions and open perspectives in an expanding clinical practice. American Journal of Medical Genetics 129C:1, 56-64
CrossRef344
Kriege, Mieke, Brekelmans, Cecile T.M., Boetes, Carla, Besnard, Peter E., Zonderland, Harmine M., Obdeijn, Inge Marie, Manoliu, Radu A., Kok, Theo, Peterse, Hans, Tilanus-Linthorst, Madeleine M.A., Muller, Sara H., Meijer, Sybren, Oosterwijk, Jan C., Beex, Louk V.A.M., Tollenaar, Rob A.E.M., de Koning, Harry J., Rutgers, Emiel J.T., Klijn, Jan G.M., . (2004) Efficacy of MRI and Mammography for Breast-Cancer Screening in Women with a Familial or Genetic Predisposition. New England Journal of Medicine 351:5, 427-437
Full Text345
Fady Khoury-Collado, Allan T. Bombard. (2004) Hereditary Breast and Ovarian Cancer: What the Primary Care Physician Should Know. Obstetrical & Gynecological Survey 59:7, 537-542
CrossRef346
Nina Hallowell, James Mackay, Martin Richards, Martin Gore, Ian Jacobs. (2004) High-Risk Premenopausal Women's Experiences of Undergoing Prophylactic Oophorectomy: A Descriptive Study. Genetic Testing 8:2, 148-156
CrossRef347
Starlene Loader, Cleveland G. Shields, Peter T. Rowley. (2004) Impact of Genetic Testing for Breast–Ovarian Cancer Susceptibility. Genetic Testing 8:1, 1-12
CrossRef348
C. Foster, D. G. R. Evans, R. Eeles, D. Eccles, S. Ashley, L. Brooks, T. Cole, J. Cook, R. Davidson, H. Gregory, J. Mackay, P. J. Morrison, M. Watson. (2004) Non-Uptake of Predictive Genetic Testing for BRCA1/2 among Relatives of Known Carriers: Attributes, Cancer Worry, and Barriers to Testing in a Multicenter Clinical Cohort. Genetic Testing 8:1, 23-29
CrossRef349
Patricia A. Mote, Jennifer A. Leary, Kelly A. Avery, Kerstin Sandelin, Georgia Chenevix-Trench, , Judy A. Kirk, Christine L. Clarke. (2004) Germ-line mutations inBRCA1 orBRCA2 in the normal breast are associated with altered expression of estrogen-responsive proteins and the predominance of progesterone receptor A. Genes, Chromosomes and Cancer 39:3, 236-248
CrossRef350
Alan B Hollingsworth, S.Eva Singletary, Monica Morrow, Darius S Francescatti, Joyce A O'Shaughnessy, Anne-Renee Hartman, Becky Haddad, Freya R Schnabel, Victor G Vogel. (2004) Current comprehensive assessment and management of women at increased risk for breast cancer. The American Journal of Surgery 187:3, 349-362
CrossRef351
André Nkondjock, Parviz Ghadirian. (2004) Epidemiology of breast cancer among BRCA mutation carriers: an overview. Cancer Letters 205:1, 1-8
CrossRef352
Louise Bouchard, I Blancquaert, F Eisinger, W.D Foulkes, G Evans, H Sobol, C Julian-Reynier. (2004) Prevention and genetic testing for breast cancer: variations in medical decisions. Social Science & Medicine 58:6, 1085-1096
CrossRef353
A.R McEwen, D.T McConnell, D.N Kenwright, D.J Gaskell, A Cherry, A.M.J Kidd. (2004) Occult cancer of the fallopian tube in a BRCA2 germline mutation carrier at prophylactic salpingo-oophorectomy. Gynecologic Oncology 92:3, 992-994
CrossRef354
Maren T. Scheuner, Paula W. Yoon, Muin J. Khoury. (2004) Contribution of Mendelian disorders to common chronic disease: Opportunities for recognition, intervention, and prevention. American Journal of Medical Genetics 125C:1, 50-65
CrossRef355
Beth Y. Karlan. (2004) Defining cancer risks for BRCA germline mutation carriers: implications for surgical prophylaxis. Gynecologic Oncology 92:2, 519-520
CrossRef356
Anne-Renee Hartman, Bruce L. Daniel, Allison W. Kurian, Meredith A. Mills, Kent W. Nowels, Frederick M. Dirbas, Kerry E. Kingham, Nicki M. Chun, Robert J. Herfkens, James M. Ford, Sylvia K. Plevritis. (2004) Breast magnetic resonance image screening and ductal lavage in women at high genetic risk for breast carcinoma. Cancer 100:3, 479-489
CrossRef357
Luna Kadouri, Zsofia Kote-Jarai, Douglas F. Easton, Ayala Hubert, Rifat Hamoudi, Benjamin Glaser, Dvorah Abeliovich, Tamar Peretz, Rosalind A. Eeles. (2004) Polyglutamine repeat length in theAIB1 gene modifies breast cancer susceptibility inBRCA1 carriers. International Journal of Cancer 108:3, 399-403
CrossRef358
Luis Robles-d
az, Deborah J Goldfrank, Noah D Kauff, Mark Robson, Kenneth Offit. (2004) Hereditary ovarian cancer in Ashkenazi Jews. Familial Cancer 3:3-4, 259-264
CrossRef359
Motohiro Takeda, Takanori Ishida, Kohji Ohnuki, Akihiko Suzuki, Masato Sakayori, Chikashi Ishioka, Tadashi Nomizu, Shinzaburou Noguchi, Yoichi Matsubara, Noriaki Ohuchi. (2004) Collaboration of breast cancer clinic and genetic counseling division for BRCA1 and BRCA2 mutation family in Japan. Breast Cancer 11:1, 30-32
CrossRef360
Olufunmilayo I. Olopade, Grazia Artioli. (2004) Efficacy of Risk-Reducing Salpingo-Oophorectomy in Women with BRCA-1 and BRCA-2 Mutations. The Breast Journal 10:s1, S5-S9
CrossRef361
Murray Joseph Casey, Chhanda Bewtra. (2004) Peritoneal carcinoma in women with genetic susceptibility: implications for Jewish populations. Familial Cancer 3:3-4, 265-281
CrossRef362
Robert F. Ozols, Michael A. Bookman, Denise C. Connolly, Mary B. Daly, Andrew K. Godwin, Russell J. Schilder, Xiangxi Xu, Thomas C. Hamilton. (2004) Focus on epithelial ovarian cancer. Cancer Cell 5:1, 19-24
CrossRef363
Peter W. Schlosshauer, Carmel J. Cohen, Frederique Penault-Llorca, Carlos R. Miranda, Yves-Jean Bignon, Jacques Dauplat, Liane Deligdisch. (2003) Prophylactic oophorectomy. Cancer 98:12, 2599-2606
CrossRef364
Ann H Partridge, Eric P Winer, Harold J Burstein. (2003) Follow-up care of breast cancer survivors. Seminars in Oncology 30:6, 817-825
CrossRef365
Maria de Carvalho, Jean Jenkins, Michele Nehrebecky, Lynda Lahl. (2003) The Role of Estrogens in BRCA1/2 Mutation Carriers. Cancer Nursing 26:6, 421???430
CrossRef366
Carolyn Y Fang, Suzanne M Miller, John Malick, James Babb, Paul F Engstrom, Mary B Daly. (2003) Psychosocial correlates of intention to undergo prophylactic oophorectomy among women with a family history of ovarian cancer. Preventive Medicine 37:5, 424-431
CrossRef367
Robin L. Bennett, Heather L. Hampel, Jessica B. Mandell, Joan H. Marks. (2003) Genetic counselors: translating genomic science into clinical practice. Journal of Clinical Investigation 112:9, 1274-1279
CrossRef368
S. Narod. (2003) Re: Roles of Radiation Dose, Chemotherapy, and Hormonal Factors in Breast Cancer Following Hodgkin's Disease. CancerSpectrum Knowledge Environment 95:20, 1552-1552
CrossRef369
Janusz Menkiszak, Jacek Gronwald, Bohdan G
CrossRef370
B. Meiser, P. Butow, M. Price, B. Bennett, G. Berry, K. Tucker. (2003) Attitudes to Prophylactic Surgery and Chemoprevention in Australian Women at Increased Risk for Breast Cancer. Journal of Women's Health 12:8, 769-778
CrossRef371
Francesmary Modugno. (2003) Ovarian cancer and high-risk women—implications for prevention, screening, and early detection. Gynecologic Oncology 91:1, 15-31
CrossRef372
Cabot, Richard C.Harris, Nancy Lee, McNeely, William F., Shepard, Jo-Anne O., Ebeling, Sally H.Ellender, Stacey M.Peters, Christine C., Ryan, Paula D., Haber, Daniel A., Shannon, Kristen M., Smith, Barbara L., Fan, Melinda J., . (2003) Case 28-2003. New England Journal of Medicine 349:11, 1076-1082
Full Text373
Christine E. Koil, Jessica N. Everett, Leah Hoechstetter, Rick E. Ricer, Karen M. Huelsman. (2003) Differences in physician referral practices and attitudes regarding hereditary breast cancer by clinical practice location. Genetics in Medicine 5:5, 364-369
CrossRef374
(2003) Breast-Cancer Genomics. New England Journal of Medicine 349:9, 910-911
Full Text375
Victor G Vogel. (2003) Management of the high-risk patient. Surgical Clinics of North America 83:4, 733-751
CrossRef376
Cl Scott, DG Iorgulescu, HJ Thorne, MA Henderson, KA Phillips, . (2003) Clinical, pathological and genetic features of women at high familial risk of breast cancer undergoing prophylactic mastectomy. Clinical Genetics 64:2, 111-121
CrossRef377
M. Friedlander, B. Thewes. (2003) Counting the costs of treatment: the reproductive and gynaecological consequences of adjuvant therapy in young women with breast cancer. Internal Medicine Journal 33:8, 372-379
CrossRef378
Andrew J Li, Beth Y Karlan. (2003) Surgical advances in the treatment of ovarian cancer. Hematology/Oncology Clinics of North America 17:4, 945-956
CrossRef379
J. L. Rutter, S. Wacholder, A. Chetrit, F. Lubin, J. Menczer, S. Ebbers, M. A. Tucker, J. P. Struewing, P. Hartge. (2003) Gynecologic Surgeries and Risk of Ovarian Cancer in Women With BRCA1 and BRCA2 Ashkenazi Founder Mutations: An Israeli Population-Based Case-Control Study. JNCI Journal of the National Cancer Institute 95:14, 1072-1078
CrossRef380
H. M. Klaren, L. J. van't Veer, F. E. van Leeuwen, M. A. Rookus. (2003) Potential for Bias in Studies on Efficacy of Prophylactic Surgery for BRCA1 and BRCA2 Mutation. JNCI Journal of the National Cancer Institute 95:13, 941-947
CrossRef381
A.N. Freedman, L. Wideroff, L. Olson, W. Davis, C. Klabunde, K.P. Srinath, B.B. Reeve, R.T. Croyle, R. Ballard-Barbash. (2003) US physicians' attitudes toward genetic testing for cancer susceptibility. American Journal of Medical Genetics 120A:1, 63-71
CrossRef382
Guttmacher, Alan E., Collins, Francis S., , Wooster, Richard, Weber, Barbara L., . (2003) Breast and Ovarian Cancer. New England Journal of Medicine 348:23, 2339-2347
Full Text383
C. J. Asperen, G. H. Bock. (2003) Erfelijke vormen van mammacarcinoomerfelijk carcinoom. Bijblijven 19:6, 249-254
CrossRef384
Martee L Hensley, Mark E Robson, Noah D Kauff, Beata Korytowsky, Mercedes Castiel, Jamie Ostroff, Karen Hurley, Lucy E Hann, Jasmine Colon, David Spriggs. (2003) Pre- and postmenopausal high-risk women undergoing screening for ovarian cancer: anxiety, risk perceptions, and quality of life. Gynecologic Oncology 89:3, 440-446
CrossRef385
Mark Robson, Martee Hensley, Richard Barakat, Carol Brown, Dennis Chi, Elizabeth Poynor, Kenneth Offit. (2003) Quality of life in women at risk for ovarian cancer who have undergone risk-reducing oophorectomy. Gynecologic Oncology 89:2, 281-287
CrossRef386
Noah D. Kauff, Edi Brogi, Lauren Scheuer, Dorothy R. Pathak, Patrick I. Borgen, Clifford A. Hudis, Kenneth Offit, Mark E. Robson. (2003) Epithelial lesions in prophylactic mastectomy specimens from women withBRCA mutations. Cancer 97:7, 1601-1608
CrossRef387
Elizabeth Swisher. (2003) Prophylactic surgery and other strategies for reducing the risk of familial ovarian cancer. Current Treatment Options in Oncology 4:2, 105-110
CrossRef388
Terence J. Colgan. (2003) Challenges in the Early Diagnosis and Staging of Fallopian-Tube Carcinomas Associated with BRCA Mutations. International Journal of Gynecological Pathology 22:2, 109-120
CrossRef389
Francesco Baudi, Loredana De Paola, Barbara Quaresima, Maria Concetta Faniello, Giuseppina Fersini, Simona Gasparro, Giuliano Fabiani, Lorenza Driul, Angela D'Elia, Sara Casarsa, Diego Marchesoni, Giuseppe Damante, Giovanni Cuda, Francesco Costanzo, Salvatore Venuta. (2003) A novel Q3034R BRCA2 germline mutation identified in a fallopian tube cancer patient. Cancer Letters 191:2, 211-214
CrossRef390
Teresa Doksum, Barbara A. Bernhardt, Neil A. Holtzman. (2003) Does knowledge about the genetics of breast cancer differ between nongeneticist physicians who do or do not discuss or order BRCA testing?. Genetics in Medicine 5:2, 99-105
CrossRef391
Wood, Alastair J.J., , Riggs, B. Lawrence, Hartmann, Lynn C., . (2003) Selective Estrogen-Receptor Modulators — Mechanisms of Action and Application to Clinical Practice. New England Journal of Medicine 348:7, 618-629
Full Text392
Cecile T.M. Brekelmans. (2003) Risk factors and risk reduction of breast and ovarian cancer. Current Opinion in Obstetrics and Gynecology 15:1, 63-68
CrossRef393
Sara Lewis Usha Menon, Usha Menon. (2003) Screening for ovarian cancer. Expert Review of Anticancer Therapy 3:1, 55-62
CrossRef394
John R. Goffin, Pierre O. Chappuis, Louis R. B
CrossRef395
Marc S Williams. (2003) Can Genomics Deliver on the Promise of Improved Outcomes and Reduced Costs?. Disease Management & Health Outcomes 11:5, 277-290
CrossRef396
Jennifer O'Rourke, Suzanne M. Mahon. (2003) A Comprehensive Look at the Early Detection of Ovarian Cancer. Clinical Journal of Oncology Nursing 7:1, 41-47
CrossRef397
Fred Gilbert. (2002) Editor's Comment: Colon Cancer Carrier Screening Enters the Genetic Testing Arena. Genetic Testing 6:4, 271-272
CrossRef398
Dimitrios H. Roukos, Niki J. Agnanti, Evangelos Paraskevaidis, Angelos M. Kappas. (2002) Approaching the dilemma between prophylactic bilateral mastectomy or oophorectomy for breast and ovarian cancer prevention in carriers ofBRCA1 orBRCA2 mutations. Annals of Surgical Oncology 9:10, 941-943
CrossRef399
(2002) Oophorectomy in Carriers of BRCA Mutations. New England Journal of Medicine 347:13, 1037-1040
Full Text400
Richard D Kennedy, Jennifer E Quinn, Patrick G Johnston, D Paul Harkin. (2002) BRCA1: mechanisms of inactivation and implications for management of patients. The Lancet 360:9338, 1007-1014
CrossRef401
Vanessa L. Zimmerman. (2002) BRCA Gene Mutations and Cancer. AJN, American Journal of Nursing 102:8, 28-37
CrossRef402
Bruce G Haffty. (2002) Management of early-onset breast cancer and BRCA1 or BRCA2 status. The Lancet 360:9333, 640-641
CrossRef403
Dimitrios H. Roukos, Aggelos M. Kappas, Epameinondas Tsianos. (2002) Role of surgery in the prophylaxis of hereditary cancer syndromes. Annals of Surgical Oncology 9:7, 607-609
CrossRef404
Fred Gilbert. (2002) Editor's Comment: Questions Raised by BRCA1/2 -Carrier Screening Programs. Genetic Testing 6:2, 71-74
CrossRef405
Haber, Daniel, . (2002) Prophylactic Oophorectomy to Reduce the Risk of Ovarian and Breast Cancer in Carriers of BRCA Mutations. New England Journal of Medicine 346:21, 1660-1662
Full Text
- Letters
